Johnson & Johnson (JNJ) 10-Q 8 May 17 2017 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Apr. 02, 2017	Apr. 28, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	JOHNSON & JOHNSON
Entity Central Index Key	200,406
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Apr. 2, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Common Stock, Shares Outstanding		2,693,833,081

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Apr. 02, 2017	Jan. 01, 2017
Current assets:
Cash and cash equivalents	$ 20,909	$ 18,972
Marketable securities	18,434	22,935
Accounts receivable, trade, less allowances for doubtful accounts $246 (2016, $252)	12,300	11,699
Inventories (Note 2)	8,878	8,144
Prepaid expenses and other	2,826	3,282
Total current assets	63,347	65,032
Property, plant and equipment at cost	38,696	37,773
Less: accumulated depreciation	(22,505)	(21,861)
Property, plant and equipment, net	16,191	15,912
Intangible assets, net (Note 3)	29,466	26,876
Goodwill (Note 3)	24,844	22,805
Deferred taxes on income	6,380	6,148
Other assets	4,690	4,435
Total assets	144,918	141,208
Current liabilities:
Loans and notes payable	5,355	4,684
Accounts payable	6,082	6,918
Accrued liabilities	5,262	5,635
Accrued rebates, returns and promotions	5,451	5,403
Accrued compensation and employee related obligations	1,836	2,676
Accrued taxes on income	1,133	971
Total current liabilities	25,119	26,287
Long-term debt (Note 4)	27,015	22,442
Deferred taxes on income	3,308	2,910
Employee related obligations	9,609	9,615
Other liabilities	9,526	9,536
Total liabilities	74,577	70,790
Shareholders’ equity:
Common stock — par value $1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)	3,120	3,120
Accumulated other comprehensive income (loss) (Note 7)	(14,522)	(14,901)
Retained earnings	111,643	110,551
Less: common stock held in treasury, at cost (424,934,000 and 413,332,000 shares)	29,900	28,352
Total shareholders’ equity	70,341	70,418
Total liabilities and shareholders' equity	$ 144,918	$ 141,208

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) shares in Thousands, $ in Millions	Apr. 02, 2017	Jan. 01, 2017
Current assets:
Allowances for doubtful accounts	$ 246	$ 252
Shareholders' equity:
Common stock, par value per share	$ 1	$ 1
Common stock, shares authorized	4,320,000	4,320,000
Common stock, shares issued	3,119,843	3,119,843
Treasury stock, shares	424,934	413,332

Consolidated Statements of Earn

Consolidated Statements of Earnings - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Apr. 02, 2017	Apr. 03, 2016
Income Statement [Abstract]
Sales to customers (Note 9)	$ 17,766	$ 17,482
Sales to customers percent to sales	100.00%	100.00%
Cost of products sold	$ 5,386	$ 5,329
Cost of products sold percent to sales	30.30%	30.50%
Gross profit	$ 12,380	$ 12,153
Gross profit percent to sales	69.70%	69.50%
Selling, marketing and administrative expenses	$ 4,737	$ 4,688
Selling marketing and administrative expenses percent to sales	26.60%	26.80%
Research and development expense	$ 2,060	$ 2,013
Research and development expense percent to sales	11.60%	11.50%
Interest income	$ (121)	$ (83)
Interest income percent to sales	(0.70%)	(0.50%)
Interest expense, net of portion capitalized	$ 204	$ 160
Interest expense, net of portion capitalized percent to sales	1.20%	0.90%
Other (income) expense, net	$ (160)	$ (39)
Other (income) expense, net percent to sales	(0.90%)	(0.20%)
Restructuring (Note 12)	$ 85	$ 120
Restructuring charge percent to sales	0.50%	0.70%
Earnings before provision for taxes on income	$ 5,575	$ 5,294
Earnings before provision for taxes on income percent to sales	31.40%	30.30%
Provision for taxes on income (Note 5)	$ 1,153	$ 837
Provision for taxes on income perent to sales	6.50%	4.80%
NET EARNINGS	$ 4,422	$ 4,457
Net earnings percent to sales	24.90%	25.50%
NET EARNINGS PER SHARE (Note 8)
Basic (per share)	$ 1.63	$ 1.62
Diluted (per share)	1.61	1.59
CASH DIVIDENDS PER SHARE	$ 0.80	$ 0.75
AVG. SHARES OUTSTANDING
Basic (shares)	2,706.6	2,757.2
Diluted (shares)	2,754.5	2,803.8

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended
	Apr. 02, 2017	Apr. 03, 2016
Statement of Comprehensive Income [Abstract]
Net earnings	$ 4,422	$ 4,457
Other comprehensive income (loss), net of tax
Foreign currency translation	395	879
Securities:
Unrealized holding gain (loss) arising during period	89	(56)
Reclassifications to earnings	(179)	(82)
Net change	(90)	(138)
Employee benefit plans:
Prior service cost amortization during period	(4)	(4)
Gain (loss) amortization during period	123	106
Net change	119	102
Derivatives & hedges:
Unrealized gain (loss) arising during period	(224)	(191)
Reclassifications to earnings	179	122
Net change	(45)	(69)
Other comprehensive income (loss)	379	774
Comprehensive income	$ 4,801	$ 5,231

Consolidated Statements of Com6

Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($) $ in Millions	3 Months Ended
	Apr. 02, 2017	Apr. 03, 2016
Consolidated Statement of Comprehensive Income [Abstract]
Securities	$ 48	$ 74
Employee Benefits	60	48
Derivatives & Hedges	$ 24	$ 37

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	3 Months Ended
	Apr. 02, 2017	Apr. 03, 2016
CASH FLOW FROM OPERATING ACTIVITIES
Net earnings	$ 4,422	$ 4,457
Adjustments to reconcile net earnings to cash flows from operating activities:
Depreciation and amortization of property and intangibles	912	891
Stock based compensation	229	205
Asset write-downs	37	82
Deferred tax provision	(27)	393
Accounts receivable allowances	(13)	(1)
Changes in assets and liabilities, net of effects from acquisitions and divestitures:
Increase in accounts receivable	(96)	(389)
Increase in inventories	(368)	(190)
Decrease in accounts payable and accrued liabilities	(2,030)	(2,072)
Increase in other current and non-current assets	(573)	(802)
Increase/(Decrease) in other current and non-current liabilities	420	(385)
NET CASH FLOWS FROM OPERATING ACTIVITIES	2,913	2,189
CASH FLOWS FROM INVESTING ACTIVITIES
Additions to property, plant and equipment	(560)	(639)
Proceeds from the disposal of assets/businesses, net	31	25
Acquisitions, net of cash acquired	(4,852)	(5)
Purchases of investments	(4,550)	(10,062)
Sales of investments	8,994	9,145
Other	1	(1)
NET CASH USED BY INVESTING ACTIVITIES	(936)	(1,537)
CASH FLOWS FROM FINANCING ACTIVITIES
Dividends to shareholders	(2,171)	(2,069)
Repurchase of common stock	(3,342)	(2,389)
Proceeds from short-term debt	719	95
Retirement of short-term debt	(195)	(4,172)
Proceeds from long-term debt, net of issuance costs	4,464	7,435
Retirement of long-term debt	(2)	(14)
Proceeds from the exercise of stock options/employee withholding tax on stock awards, net	402	510
Other	(25)	0
NET CASH USED BY FINANCING ACTIVITIES	(150)	(604)
Effect of exchange rate changes on cash and cash equivalents	110	81
Increase in cash and cash equivalents	1,937	129
Cash and Cash equivalents, beginning of period	18,972	13,732
CASH AND CASH EQUIVALENTS, END OF PERIOD	20,909	13,861
Acquisitions
Fair value of assets acquired	5,250	7
Fair value of liabilities assumed and noncontrolling interests	(398)	(2)
Net cash paid for acquisitions	$ 4,852	$ 5

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Apr. 02, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	The accompanying unaudited interim consolidated financial statements and related notes should be read in conjunction with the audited Consolidated Financial Statements of Johnson & Johnson and its subsidiaries (the Company) and related notes as contained in the Company’s Annual Report on Form 10-K for the fiscal year ended January 1, 2017 . The unaudited interim financial statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair statement of the results for the periods presented. New Accounting Standards Adopted in Quarter Ending April 2, 2017 During the fiscal first quarter of 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2016-07 Investments - Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting. The amendments in the update eliminate the requirement that when an investment qualifies for the use of the equity method as a result of an increase in the level of ownership interest or degree of influence, an investor must adjust the investment, results of operations, and retained earnings retroactively on a step by step basis as if the equity method had been in effect during all previous periods that the investment had been held. The amendments in this update are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. The amendments should be applied prospectively upon their effective date to increases in the level of ownership interest or degree of influence that result in the application of the equity method. The adoption of this standard did not have a material impact on the presentation of the Company's consolidated financial statements. During the fiscal second quarter of 2015, the FASB issued Accounting Standards Update 2015-11: Simplifying the Measurement of Inventory. This update requires inventory to be measured at the lower of cost or net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. This update is effective for the Company for all annual and interim periods beginning after December 15, 2016. The amendments in this update should be applied prospectively. This update did not have any material impact on the Company’s consolidated financial statements. Recently Issued Accounting Standards Not Adopted as of April 2, 2017 During the fiscal first quarter of 2017, the FASB issued Accounting Standards Update 2017-07: Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost. This update requires that an employer disaggregate the service cost component from the other components of net periodic benefit cost (“NPBC”). In addition, only the service cost component will be eligible for capitalization. This update is effective for the Company for all annual and interim periods beginning after December 15, 2017. Early adoption is permitted as of the beginning of an annual period for which financial statements (interim or annual) have not been issued or made available for issuance. The Company will adopt this new standard in 2018. The amendments in this Update should be applied retrospectively for the presentation of the service cost component and the other components of NPBC in the income statement and prospectively, on and after the effective date, for the capitalization of the service cost component of NPBC in assets. The Company is assessing the retroactive restatement methodology and impact to the individual line items on Consolidated Statement of Earnings. The Company does not expect there to be a material impact to net earnings. During the fiscal first quarter of 2017, the FASB issued Accounting Standard Update 2017-05: Other Income-Gains and Losses from the Derecognition of Nonfinancial Assets. This update clarifies the scope of asset derecognition guidance, adds guidance for partial sales of nonfinancial assets and clarifies recognizing gains and losses from the transfer of nonfinancial assets in contracts with noncustomers. This update will be effective for the Company for its annual and interim reporting periods beginning after December 15, 2017, the same time as the amendments in Update 2014-09 Revenue from Contracts with Customers. This update allows the Company to choose either a full retrospective method or modified retrospective method upon adoption. The Company is currently assessing the impact of the future adoption of this standard on its financial statements. During the fiscal first quarter of 2017, the FASB issued Accounting Standard Update 2017-04: Simplifying the Test for Goodwill Impairment. This update simplifies how an entity is required to test goodwill for impairment. A goodwill impairment will now be measured by the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. This update will be effective for the Company for its annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. Early adoption is permitted. This update should be applied prospectively. The Company is currently assessing the impact of the future adoption of this standard on its financial statements. During the fiscal first quarter of 2017, the FASB issued Accounting Standard Update 2017-01: Clarifying the Definition of a Business. This update narrows the definition of a business by providing a screen to determine when an integrated set of assets and activities is not a business. The screen specifies that an integrated set of assets and activities is not a business if substantially all of the fair value of the gross assets acquired or disposed of is concentrated in a single or a group of similar identifiable assets. This update will be effective for the Company for annual periods beginning after December 15, 2017, including interim periods within those annual periods. Early adoption is permitted. This update should be applied prospectively. The Company is currently assessing the impact of the future adoption of this standard on its financial statements. During the fiscal fourth quarter of 2016, the FASB issued Accounting Standards Update 2016-16 Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory. This update removes the current exception in US GAAP prohibiting entities from recognizing current and deferred income tax expenses or benefits related to transfer of assets, other than inventory, within the consolidated entity. The current exception to defer the recognition of any tax impact on the transfer of inventory within the consolidated entity until it is sold to a third party remains unaffected. The amendments in this update are effective for public entities for annual reporting periods beginning after December 15, 2017. Early adoption is permitted and should be in the first interim period if an entity issues interim financial statements. The Company is currently assessing the impact of the future adoption of this standard on its consolidated financial statements. During the fiscal third quarter of 2016, the FASB issued Accounting Standards Update 2016-15 Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. This update addresses whether to present certain specific cash flow items as operating, investing or financing activities. The amendments in this update are effective for public entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. Early adoption is permitted, including adoption in an interim period. The Company is currently assessing the impact of the future adoption of this standard on its consolidated Statements of Cash Flows. During the fiscal first quarter of 2016, the FASB issued Accounting Standards Update 2016-02 Leases (Topic 842). This update requires the recognition of lease assets and lease liabilities on the balance sheet for all lease obligations and disclosing key information about leasing arrangements. This update requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under current generally accepted accounting principles. This update will be effective for the Company for all annual and interim periods beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted. The update is required to be adopted using a modified retrospective approach. The Company anticipates that most of its operating leases will result in the recognition of additional assets and the corresponding liabilities on its Consolidated Balance Sheets, however does not expect to have a material impact on the financial position. The actual impact will depend on the Company's lease portfolio at the time of adoption. The Company continues to assess all implications of the standard and related financial disclosures. During the fiscal first quarter of 2016, the FASB issued Accounting Standards Update 2016-01 Financial Instruments: Recognition and Measurement of Financial Assets and Financial Liabilities. The amendments in this update supersede the guidance to classify equity securities with readily determinable fair values into different categories (that is, trading or available-for-sale) and require equity securities to be measured at fair value with changes in the fair value recognized through net income. The standard amends financial reporting by providing relevant information about an entity’s equity investments and reducing the number of items that are recognized in other comprehensive income. This update will be effective for the Company for annual periods beginning after December 15, 2017, and interim periods within those annual periods. The Company is unable to estimate the impact of the future adoption of this standard on its financial statements as it will depend on the equity investments as of the adoption date. During the fiscal second quarter of 2014, the FASB issued Accounting Standards Update 2014-09: Revenue from Contracts with Customers, which, along with amendments issued in 2015 and 2016, will replace substantially all current U.S. GAAP guidance on this topic and eliminate industry-specific guidance. Early adoption of this standard is permitted but not before the original effective date for all annual periods and interim reporting periods beginning after December 15, 2017. The guidance permits two methods of adoption: full retrospective method (retrospective application to each prior reporting period presented) or modified retrospective method (retrospective application with the cumulative effect of initially applying the guidance recognized at the date of initial application and providing certain additional disclosures). While the Company continues to evaluate the effect of the standard, preliminarily, it does not anticipate a material impact on its financial statements. To complete the assessment of the impact of the standard to the financial statements, the Company continues to assess all implications of the standard, method of adoption and related financial disclosures. Additionally, the Company continues to monitor modifications, clarifications and interpretations issued by the FASB that may affect current conclusions.

Inventories

Inventories	3 Months Ended
	Apr. 02, 2017
Inventory Disclosure [Abstract]
Inventories	INVENTORIES (Dollars in Millions) April 2, 2017 January 1, 2017 Raw materials and supplies $ 1,046 952 Goods in process 2,121 2,185 Finished goods 5,711 5,007 Total inventories $ 8,878 8,144 Inventory of $65 million was classified as held for sale, and reported in prepaid expenses and other on the Consolidated Balance Sheet, related to the divestiture of the Codman Neurosurgery business which was pending as of April 2, 2017.

Intangible Assets and Goodwill

Intangible Assets and Goodwill	3 Months Ended
	Apr. 02, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill	INTANGIBLE ASSETS AND GOODWILL Intangible assets that have finite useful lives are amortized over their estimated useful lives. The latest annual impairment assessment of goodwill and indefinite lived intangible assets was completed in the fiscal fourth quarter of 2016 . Future impairment tests for goodwill and indefinite lived intangible assets will be performed annually in the fiscal fourth quarter, or sooner, if warranted. (Dollars in Millions) April 2, 2017 January 1, 2017 Intangible assets with definite lives: Patents and trademarks — gross $ 11,311 10,521 Less accumulated amortization 5,226 5,076 Patents and trademarks — net 6,085 5,445 Customer relationships and other intangibles — gross 19,653 17,615 Less accumulated amortization 6,741 6,515 Customer relationships and other intangibles — net 12,912 11,100 Intangible assets with indefinite lives: Trademarks 6,957 6,888 Purchased in-process research and development 3,512 3,443 Total intangible assets with indefinite lives 10,469 10,331 Total intangible assets — net $ 29,466 26,876 Goodwill as of April 2, 2017 was allocated by segment of business as follows: (Dollars in Millions) Consumer Pharm Med Devices Total Goodwill, net at January 1, 2017 $ 8,263 2,840 11,702 22,805 Goodwill, related to acquisitions 10 — 2,040 2,050 Currency translation/Other 71 14 (96 ) (1) (11 ) Goodwill, net at April 2, 2017 $ 8,344 2,854 13,646 24,844 (1) Net of $106 million classified as held for sale, reported in other assets on the Consolidated Balance Sheet, related to the divestiture of the Codman Neurosurgery business which was pending as of April 2, 2017. The weighted average amortization periods for patents and trademarks and customer relationships and other intangible assets are 19 years and 23 years, respectively. The amortization expense of amortizable intangible assets included in cost of products sold was $329 million and $282 million for the fiscal three months ended April 2, 2017 and April 3, 2016 , respectively. The estimated amortization expense for the five succeeding years approximates $1.5 billion , before tax, per year. Intangible asset write-downs are included in Other (income) expense, net. The primary driver of the increase to intangible assets and goodwill is related to the Abbott Medical Optics (AMO) acquisition in the fiscal first quarter of 2017, which resulted in the recording of $2.3 billion to intangible assets and $1.9 billion to goodwill. The intangible assets and goodwill amounts related to the AMO acquisition are based on the preliminary purchase price allocation. See Note 10 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Apr. 02, 2017
Fair Value Disclosures [Abstract]
Fair Value Measurements	FAIR VALUE MEASUREMENTS The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany products and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. The Company also uses equity collar contracts to manage exposure to market risk associated with certain equity investments. All three types of derivatives are designated as cash flow hedges. Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings. These derivatives are designated as fair value hedges. The Company uses forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features or requirements to post collateral (excluding equity collar contracts) by either the Company or the counter-party. For equity collar contracts, the Company pledged the underlying hedged marketable equity securities to the counter-party as collateral. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of April 2, 2017 , the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps, interest rate swaps and equity collar contracts of $33.1 billion , $2.3 billion , $1.8 billion , and $0.2 billion respectively. As of January 1, 2017, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps, interest rate swaps and equity collar contracts of $36.0 billion , $2.3 billion , $1.8 billion , and $0.3 billion respectively. All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction. The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Changes in the fair value of a derivative that is designated as a cash flow hedge and is highly effective are recorded in accumulated other comprehensive income until the underlying transaction affects earnings, and are then reclassified to earnings in the same account as the hedged transaction. Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur. Gains and losses on net investment hedges are accounted for through the currency translation account. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued. Hedge ineffectiveness, if any, is included in current period earnings in Other (income) expense, net for forward foreign exchange contracts, cross currency interest rate swaps, net investment hedges and equity collar contracts. For interest rate swaps designated as fair value hedges, hedge ineffectiveness, if any, is included in current period earnings within interest expense. For the current reporting period, hedge ineffectiveness associated with interest rate swaps was not material. During the fiscal second quarter of 2016, the Company designated its Euro denominated notes issued in May 2016 with due dates ranging from 2022 to 2035 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates. The change in the carrying value due to remeasurement of these Euro notes resulted in a $110 million pretax loss during the fiscal first quarter of 2017, resulting in a cumulative $265 million pretax gain from hedge inception through the fiscal first quarter of 2017 reflected in foreign currency translation adjustment, within the Consolidated Statements of Comprehensive Income. As of April 2, 2017 , the balance of deferred net losses on derivatives included in accumulated other comprehensive income was $330 million after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 7. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months , excluding interest rate contracts, net investment hedges and equity collar contracts. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative. The following table is a summary of the activity related to derivatives designated as cash flow hedges for the fiscal first quarters in 2017 and 2016 : Gain/(Loss) Recognized In Accumulated OCI (1) Gain/(Loss) Reclassified From Accumulated OCI Into Income (1) Gain/(Loss) Recognized In Other Income/Expense (2) (Dollars in Millions) Fiscal Three Months Ended Cash Flow Hedges By Income Statement Caption April 2, 2017 April 3, 2016 April 2, 2017 April 3, 2016 April 2, 2017 April 3, 2016 Sales to customers (3) $ (13 ) — (33 ) (18 ) — — Cost of products sold (3) (97 ) (44 ) (31 ) (21 ) (17 ) (4 ) Research and development expense (3) (109 ) (107 ) (102 ) (95 ) 5 — Interest (income)/Interest expense, net (4) 28 12 22 8 — — Other (income) expense, net (3) (5) (33 ) (52 ) (35 ) 4 1 (3 ) Total $ (224 ) (191 ) (179 ) (122 ) (11 ) (7 ) All amounts shown in the table above are net of tax. (1) Effective portion (2) Ineffective portion (3) Forward foreign exchange contracts (4) Cross currency interest rate swaps (5) Includes equity collar contracts For the fiscal first quarters ended April 2, 2017 and April 3, 2016 , a loss of $29 million and $5 million , respectively, was recognized in Other (income) expense, net, relating to forward foreign exchange contracts not designated as hedging instruments. Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level 1 having the highest priority and Level 3 having the lowest. The fair value of a derivative financial instrument (i.e. forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company’s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The Company did not have any other significant financial assets or liabilities which would require revised valuations under this standard that are recognized at fair value. The following three levels of inputs are used to measure fair value: Level 1 — Quoted prices in active markets for identical assets and liabilities. Level 2 — Significant other observable inputs. Level 3 — Significant unobservable inputs. The Company’s significant financial assets and liabilities measured at fair value as of April 2, 2017 and January 1, 2017 were as follows: April 2, 2017 January 1, 2017 (Dollars in Millions) Level 1 Level 2 Level 3 Total Total (1) Derivatives designated as hedging instruments: Assets: Forward foreign exchange contracts (7) $ — 291 — 291 747 Interest rate contracts (2)(4)(7) — 29 — 29 31 Total — 320 — 320 778 Liabilities: Forward foreign exchange contracts (8) — 576 — 576 723 Interest rate contracts (3)(4)(8) — 345 — 345 382 Equity collar contracts (8) — 63 — 63 57 Total — 984 — 984 1,162 Derivatives not designated as hedging instruments: Assets: Forward foreign exchange contracts (7) — 26 — 26 34 Liabilities: Forward foreign exchange contracts (8) — 62 — 62 57 Available For Sale Other Investments: Equity investments (5) 1,008 — — 1,008 1,209 Debt securities (6) $ — 26,808 — 26,808 12,087 (1) 2016 assets and liabilities are all classified as Level 2 with the exception of equity investments of $1,209 million , which are classified as Level 1. (2) Includes $21 million and $23 million of non-current other assets for April 2, 2017 and January 1, 2017, respectively. (3) Includes $345 million and $382 million of non-current other liabilities for April 2, 2017 and January 1, 2017, respectively. (4) Includes cross currency interest rate swaps and interest rate swaps. (5) Classified as non-current other assets with the exception of $246 million of current other assets for April 2, 2017 . The original cost of the equity investments were $471 million and $520 million as of April 2, 2017 and January 1, 2017, respectively. The unrealized gains were $607 million and $757 million as of April 2, 2017 and January 1, 2017, respectively. The unrealized losses were $70 million and $68 million as of April 2, 2017 and January 1, 2017, respectively. (6) Classified as cash equivalents and current marketable securities. (7) Classified as other current assets. (8) Classified as accounts payable. The Company's cash, cash equivalents and current marketable securities as of April 2, 2017 comprised: April 2, 2017 (Dollars in Millions) Carrying Amount Unrecognized Gain Unrecognized Loss Estimated Fair Value Cash & Cash Equivalents Current Marketable Securities Cash $ 2,205 — — 2,205 2,205 U.S. Gov't Securities (1) 1,899 — — 1,899 — 1,899 Other Sovereign Securities (1) 90 — — 90 — 90 U.S. Reverse repurchase agreements 4,726 — — 4,726 4,726 — Other Reverse repurchase agreements 214 — — 214 214 Corporate debt securities (1) 80 — — 80 — 80 Money market funds 1,923 — — 1,923 1,923 Time deposits (1) 1,152 — — 1,152 1,152 Subtotal 12,289 — — 12,289 10,220 2,069 Unrealized Gain Unrealized Loss Gov't securities 24,903 6 (42 ) 24,867 10,689 14,178 Other Sovereign Securities 91 — — 91 — 91 Corporate debt securities 1,857 2 (9 ) 1,850 — 1,850 Equity investments 23 223 — 246 — 246 Subtotal Available for Sale (2) $ 26,874 231 (51 ) 27,054 10,689 16,365 Total cash, cash equivalents and current marketable securities 20,909 18,434 (1) Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. (2) Available for sale securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income. Fair value of government securities and obligations and corporate debt securities was estimated using quoted broker prices and significant other observable inputs. The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available for current operations and are classified as cash equivalents and current marketable securities. The excess of the estimated fair value over the carrying value of cash equivalents and current marketable securities was $0.2 billion at January 1, 2017. The contractual maturities of the available for sale securities at April 2, 2017 are as follows: (Dollars in Millions) Cost Basis Fair Value Due within one year $ 16,571 16,568 Due after one year through five years 10,280 10,240 Due after five years through ten years — — Total debt securities $ 26,851 26,808 Financial Instruments not measured at Fair Value: The following financial liabilities are held at carrying amount on the consolidated balance sheet as of April 2, 2017 : (Dollars in Millions) Carrying Amount Estimated Fair Value Financial Liabilities Current Debt $ 5,355 5,355 Non-Current Debt 5.15% Debentures due 2018 899 942 1.65% Notes due 2018 601 605 4.75% Notes due 2019 (1B Euro 1.0725) 1,069 1,204 1.875% Notes due 2019 501 505 0.89% Notes due 2019 300 301 1.125% Notes due 2019 699 696 3% Zero Coupon Convertible Subordinated Debentures due in 2020 83 142 2.95% Debentures due 2020 546 566 3.55% Notes due 2021 447 473 2.45% Notes due 2021 349 355 1.65% Notes due 2021 997 986 0.250% Notes due 2022 (1B Euro 1.0725) 1,069 1,072 2.25% Notes due 2022 994 995 6.73% Debentures due 2023 249 310 3.375% Notes due 2023 807 851 2.05% Notes due 2023 497 486 0.650% Notes due 2024 (750MM Euro 1.0725) 799 805 5.50% Notes due 2024 (500 MM GBP 1.2474) 617 804 2.45% Notes due 2026 1,989 1,915 2.95% Notes due 2027 995 996 1.150% Notes due 2028 (750MM Euro 1.0725) 796 805 6.95% Notes due 2029 296 401 4.95% Debentures due 2033 498 589 4.375% Notes due 2033 857 951 1.650% Notes due 2035 (1.5B Euro 1.0725) 1,590 1,646 3.55% Notes due 2036 987 981 5.95% Notes due 2037 990 1,290 3.625% Notes due 2037 1,485 1,473 5.85% Debentures due 2038 695 908 4.50% Debentures due 2040 537 592 4.85% Notes due 2041 296 345 4.50% Notes due 2043 495 548 3.70% Notes due 2046 1,970 1,929 3.75% Notes due 2047 990 982 Other 26 26 Total Non-Current Debt $ 27,015 28,475 The weighted average effective interest rate on non-current debt is 3.28% . The excess of the estimated fair value over the carrying value of debt was $1.6 billion at January 1, 2017. Fair value of the non-current debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.

Income Taxes

Income Taxes	3 Months Ended
	Apr. 02, 2017
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES The worldwide effective income tax rates for the fiscal three months of 2017 and 2016 were 20.7% and 15.8% , respectively. The Company completed its acquisition of AMO in the first fiscal quarter of 2017, and incurred incremental tax costs that were discretely recorded in the first quarter, which increased the effective tax rate by 3.8% compared to the same period in 2016. Additionally, the Company had more income in higher tax jurisdictions relative to lower tax jurisdictions as compared to 2016. These tax increases were partially offset by additional tax benefits received from stock-based compensation that either vested or were exercised during the first fiscal quarters of 2017 and 2016, which reduced the effective tax rate by 3.6% and 3.1% , respectively. As of April 2, 2017 , the Company had approximately $3.1 billion of liabilities from unrecognized tax benefits. The Company believes it is possible that audits may be completed by tax authorities in some jurisdictions over the next twelve months. The Company is not able to provide a reasonably reliable estimate of the timing of any future tax payments relating to uncertain tax positions.

Pensions and Other Postretireme

Pensions and Other Postretirement Benefits	3 Months Ended
	Apr. 02, 2017
Compensation and Retirement Disclosure [Abstract]
Pension and Other Postretirement Benefits	PENSIONS AND OTHER POSTRETIREMENT BENEFITS Components of Net Periodic Benefit Cost Net periodic benefit cost for the Company’s defined benefit retirement plans and other benefit plans for the fiscal first quarters of 2017 and 2016 include the following components: Fiscal First Quarters Ended Retirement Plans Other Benefit Plans (Dollars in Millions) April 2, 2017 April 3, 2016 April 2, 2017 April 3, 2016 Service cost $ 251 226 61 55 Interest cost 230 233 39 40 Expected return on plan assets (505 ) (492 ) (2 ) (2 ) Amortization of prior service cost/(credit) — 1 (7 ) (8 ) Recognized actuarial losses 152 124 34 34 Curtailments and settlements — 1 — — Net periodic benefit cost $ 128 93 125 119 Company Contributions For the fiscal three months ended April 2, 2017 , the Company contributed $17 million and $10 million to its U.S. and international retirement plans, respectively. The Company plans to continue to fund its U.S. defined benefit plans to comply with the Pension Protection Act of 2006. International plans are funded in accordance with local regulations.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income	3 Months Ended
	Apr. 02, 2017
Equity [Abstract]
Accumulated Other Comprehensive Income	ACCUMULATED OTHER COMPREHENSIVE INCOME Components of other comprehensive income (loss) consist of the following: Foreign Gain/(Loss) Employee Gain/(Loss) Total Accumulated Currency On Benefit On Derivatives Other Comprehensive (Dollars in Millions) Translation Securities Plans & Hedges Income (Loss) January 1, 2017 $ (9,047 ) 411 (5,980 ) (285 ) (14,901 ) Net change 395 (90 ) 119 (45 ) 379 April 2, 2017 $ (8,652 ) 321 (5,861 ) (330 ) (14,522 ) Amounts in accumulated other comprehensive income are presented net of the related tax impact. Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries. For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income. Details on reclassifications out of Accumulated Other Comprehensive Income: Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net. Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 6 for additional details. Gain/(Loss) On Derivatives & Hedges - reclassifications to earnings are recorded in the same account as the underlying transaction. See Note 4 for additional details.

Earnings Per Share

Earnings Per Share	3 Months Ended
	Apr. 02, 2017
Earnings Per Share [Abstract]
Earnings Per Share	EARNINGS PER SHARE The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal first quarters ended April 2, 2017 and April 3, 2016 : Fiscal First Quarters Ended (Shares in Millions) April 2, 2017 April 3, 2016 * Basic net earnings per share $ 1.63 1.62 Average shares outstanding — basic 2,706.6 2,757.2 Potential shares exercisable under stock option plans 141.2 145.7 Less: shares which could be repurchased under treasury stock method (94.6 ) (101.1 ) Convertible debt shares 1.3 2.0 Average shares outstanding — diluted 2,754.5 2,803.8 Diluted net earnings per share $ 1.61 1.59 *The fiscal first quarter of 2016 has been recast to reflect the adoption of ASU 2016-09. See Note 1 to the Consolidated Financial Statements in the Annual Report on Form 10-K for the fiscal year ended January 1, 2017 for more detailed information regarding the adoption of ASU 2016-09. The diluted net earnings per share calculation for both the fiscal first quarters ended April 2, 2017 and April 3, 2016 included the dilutive effect of convertible debt that was offset by the related reduction in interest expense. The diluted net earnings per share calculation for both the fiscal first quarters ended April 2, 2017 and April 3, 2016 included all shares related to stock options, as there were no options or other instruments which were anti-dilutive.

Segments of Business and Geogra

Segments of Business and Geographic Areas	3 Months Ended
	Apr. 02, 2017
Segment Reporting [Abstract]
Segments of Business and Geographic Areas	SEGMENTS OF BUSINESS AND GEOGRAPHIC AREAS SALES BY SEGMENT OF BUSINESS Fiscal First Quarters Ended (Dollars in Millions) April 2, April 3, Percent Change Consumer United States $ 1,414 1,358 4.1 % International 1,814 1,837 (1.3 ) Total 3,228 3,195 1.0 Pharmaceutical United States 4,872 4,937 (1.3 ) International 3,373 3,241 4.1 Total 8,245 8,178 0.8 Medical Devices United States 3,092 3,026 2.2 International 3,201 3,083 3.8 Total 6,293 6,109 3.0 Worldwide United States 9,378 9,321 0.6 International 8,388 8,161 2.8 Total $ 17,766 17,482 1.6 % INCOME BEFORE TAX BY SEGMENT Fiscal First Quarters Ended (Dollars in Millions) April 2, April 3, Percent Change Consumer $ 596 566 5.3 % Pharmaceutical (1) 3,663 3,344 9.5 Medical Devices (2) 1,563 1,576 (0.8 ) Segments operating profit 5,822 5,486 6.1 Less: Expense not allocated to segments (3) 247 192 Worldwide income before tax $ 5,575 5,294 5.3 % (1) Includes a gain of $0.2 billion and $0.1 billion in the fiscal first quarters of 2017 and 2016, respectively, related to the sale of certain investments in equity securities held by Johnson & Johnson Innovation - JJDC, Inc. Includes a positive adjustment of $0.2 billion to previous reserve estimates in the fiscal first quarter of 2016. (2) Includes a restructuring related charge of $161 million and $137 million in the fiscal first quarter of 2017 and 2016, respectively. Includes litigation expense of $106 million in the fiscal first quarter of 2016. (3) Amounts not allocated to segments include interest income/expense and general corporate income/expense. SALES BY GEOGRAPHIC AREA Fiscal First Quarters Ended (Dollars in Millions) April 2, 2017 April 3, 2016 Percent Change United States $ 9,378 9,321 0.6 % Europe 3,858 3,847 0.3 Western Hemisphere, excluding U.S. 1,454 1,331 9.2 Asia-Pacific, Africa 3,076 2,983 3.1 Total $ 17,766 17,482 1.6 %

Business Combinations and Dives

Business Combinations and Divestitures	3 Months Ended
	Apr. 02, 2017
Business Combinations [Abstract]
Business Combinations and Divestitures	BUSINESS COMBINATIONS AND DIVESTITURES During the fiscal first quarter of 2017, the Company acquired Abbott Medical Optics (AMO), a wholly-owned subsidiary of Abbott Laboratories, for $4.4 billion , net of cash acquired. The acquisition included ophthalmic products related to: cataract surgery, laser refractive surgery and consumer eye health. The net purchase price was primarily recorded as amortizable intangible assets for $2.3 billion and goodwill for $1.9 billion . The weighted average life of total amortizable intangibles, the majority being customer relationships, is approximately 14.5 years . The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not deductible for tax purposes. The intangible assets and goodwill amounts are based on the preliminary purchase price allocation. The assets acquired were recorded in the Medical Devices segment. Additionally, during the fiscal first quarter of 2017, the Company completed the acquisition of Torax Medical, Inc., a privately-held medical device company that manufactures and markets the LINX™ Reflux Management System for the surgical treatment of gastroesophageal reflux disease and Megadyne Medical Products, Inc., a privately-held medical device company that develops, manufactures and markets electrosurgical tools. On January 26, 2017, the Company announced a definitive transaction agreement under which the company launched an all-cash tender offer in Switzerland to acquire all of the outstanding shares of Actelion Ltd. for $280 per share, payable in U.S. dollars, for approximately $30.0 billion . As part of the transaction, immediately prior to the completion of the acquisition, Actelion will spin out its drug discovery operations and early-stage clinical development assets into a newly created Swiss biopharmaceutical company, Idorsia. The shares of Idorsia, which will be listed on the SIX Swiss Exchange (SIX), will be distributed to Actelion's shareholders as a stock dividend upon closing of the tender. The Company will initially hold 16% of the shares of Idorsia and have rights to an additional 16% of Idorsia equity through a convertible note. Actelion has established a leading franchise of differentiated, innovative products for pulmonary arterial hypertension (PAH) that is highly complementary to the existing portfolio of the Company. The addition of Actelion’s specialty in-market medicines and late-stage products is consistent with the Company's efforts to grow in attractive and complementary therapeutic areas and serve patients with serious illnesses and significant unmet medical need. Subject to the demerger, antitrust clearance and other customary closing conditions, the Company expects to complete the closing by the end of the second quarter. During the fiscal first quarter of 2017, the Company received a binding offer from Integra LifeSciences Holdings Corporation to purchase the Company's Codman Neurosurgery business for approximately $1.0 billion . As of April 2, 2017, the assets held for sale were $65 million of inventory, classified as prepaid expenses and other on the Consolidated Balance Sheet. The non-current assets classified as held for sale were $19 million of property, plant and equipment, net and $106 million of goodwill, classified as other assets on the Consolidated Balance Sheet. During the fiscal first quarter of 2017, the Company announced it is engaging in a process to evaluate potential strategic options for the Johnson & Johnson Diabetes Care Companies, specifically LifeScan, Inc., Animas Corporation, and Calibra Medical, Inc. Strategic options may include the formation of operating partnerships, joint ventures or strategic alliances, a sale of the businesses, or other alternatives either separately or together. All options will be evaluated to determine the best opportunity to drive future growth and maximize shareholder value. There can be no assurance that this process will result in any transaction or other strategic alternative of any kind therefore, there were no assets held for sale as of April 2, 2017 related to the announcement. Subsequent to the quarter, the Company completed the acquisition of Neuravi Limited, a privately-held medical device company that develops and markets medical devices for neurointerventional therapy.

Legal Proceedings

Legal Proceedings	3 Months Ended
	Apr. 02, 2017
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings	LEGAL PROCEEDINGS Johnson & Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability, intellectual property, commercial and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business. The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred and the amount of the loss can be reasonably estimated. As of April 2, 2017 , the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts already accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions. The ability to make such estimates and judgments can be affected by various factors, including whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; or there are numerous parties involved. In the Company's opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company's balance sheet, is not expected to have a material adverse effect on the Company's financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company's results of operations and cash flows for that period. PRODUCT LIABILITY Johnson & Johnson and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. The Company has established accruals for product liability claims and lawsuits in compliance with ASC 450-20 based on currently available information, which in some cases may be limited. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. To the extent adverse verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available. The most significant of these cases include the DePuy ASR™ XL Acetabular System and DePuy ASR™ Hip Resurfacing System, the PINNACLE ® Acetabular Cup System, pelvic meshes, RISPERDAL ® , XARELTO ® and JOHNSON'S ® Baby Powder. As of April 2, 2017 , in the U.S. there were approximately 2,000 plaintiffs with direct claims in pending lawsuits regarding injuries allegedly due to the DePuy ASR™ XL Acetabular System and DePuy ASR™ Hip Resurfacing System, 9,600 with respect to the PINNACLE ® Acetabular Cup System, 55,800 with respect to pelvic meshes, 16,900 with respect to RISPERDAL ® , 18,400 with respect to XARELTO ® and 3,900 with respect to JOHNSON'S ® Baby Powder. In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR ™ XL Acetabular System and DePuy ASR ™ Hip Resurfacing System used in hip replacement surgery. Claims for personal injury have been made against DePuy and Johnson & Johnson. The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip System plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 31, 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 31, 2013 and prior to February 15, 2017. This settlement program has resolved more than 9,500 claims, with more expected from the recent extension, therefore bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the U.S. settlement program and DePuy ASR ™ Hip-related product liability litigation. Claims for personal injury have also been made against DePuy and Johnson & Johnson relating to the PINNACLE ® Acetabular Cup System used in hip replacement surgery. The number of pending product liability lawsuits continues to increase, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom. The Company has established an accrual for defense costs in connection with product liability litigation associated with the PINNACLE ® Acetabular Cup System. Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson & Johnson arising out of Ethicon's pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The number of pending product liability lawsuits continues to increase, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Southern District of West Virginia. In addition, class actions and individual personal injury cases or claims have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands, Belgium, Italy and Venezuela, and class actions in Israel, Australia and Canada, seeking damages for alleged injury resulting from Ethicon's pelvic mesh devices. The Company has established an accrual with respect to product liability litigation associated with Ethicon's pelvic mesh products. Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and Johnson & Johnson arising out of the use of RISPERDAL ® , indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism, and related compounds. Lawsuits have been primarily filed in state courts in Pennsylvania, California, and Missouri. Other actions are pending in various courts in the United States and Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established an accrual with respect to product liability litigation associated with RISPERDAL ® . Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and Johnson & Johnson arising out of the use of XARELTO ® , an oral anticoagulant. The number of pending product liability lawsuits continues to increase, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Eastern District of Louisiana. In addition, cases have been filed in state courts across the United States. Many of these cases have been consolidated into a state mass tort litigation in Philadelphia, Pennsylvania; and there are coordinated proceedings in Delaware, California and Missouri. Class action lawsuits also have been filed in Canada. The Company has established an accrual for defense costs in connection with product liability litigation associated with XARELTO ® . Claims for personal injury have been made against Johnson & Johnson Consumer Inc. and Johnson & Johnson arising out of the use of JOHNSON'S ® Baby Powder. The number of pending product liability lawsuits continues to increase, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Lawsuits have been primarily filed in state courts in Missouri, New Jersey and California. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the District of New Jersey. The Company has established an accrual for defense costs in connection with product liability litigation associated with JOHNSON'S ® Baby Powder. INTELLECTUAL PROPERTY Certain subsidiaries of Johnson & Johnson are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the coverage and/or validity of the patents on various products and allegations that certain of the Company’s products infringe the patents of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset. The most significant of these matters are described below. Medical Devices In June 2009, Rembrandt Vision Technologies, L.P. (Rembrandt) filed a patent infringement lawsuit against Johnson & Johnson Vision Care, Inc. (JJVCI) in the United States District Court for the Eastern District of Texas alleging that JJVCI's manufacture and sale of its ACUVUE ® ADVANCE and ACUVUE OASYS ® Hydrogel Contact Lenses infringed Rembrandt’s U.S. Patent No. 5,712,327 and seeking monetary relief. The case was transferred to the United States District Court for the Middle District of Florida, where a trial in May 2012 resulted in a verdict of non-infringement that was subsequently upheld on appeal. In July 2014, Rembrandt sought a new trial based on alleged new evidence, which the District Court denied. In April 2016, the Court of Appeals overturned that ruling and remanded the case to the District Court for a new trial. A new trial is scheduled for August 2017. LifeScan filed a patent infringement lawsuit against UniStrip Technologies, LLC (UniStrip) in the United States District Court for the District of North Carolina in May 2014, alleging that the making and marketing of UniStrip’s strips for use in LifeScan’s blood glucose monitors infringe U.S. Patent Nos. 6,241,862 and 7,250,105 (the ’105 patent). In August 2014, the United States Patent and Trademark Office (USPTO) determined that the ’105 patent is invalid. In January 2016, the invalidity decision was upheld on appeal. LifeScan filed a motion for rehearing, which was denied. In July 2014, UniStrip brought a lawsuit against LifeScan in the United States District Court for the Eastern District of Pennsylvania, alleging antitrust violations relating to marketing practices for LifeScan strips. In March 2017, the parties settled both the antitrust and patent lawsuits. In March 2013, Medinol Ltd. (Medinol) filed a patent infringement lawsuit against Cordis Corporation (Cordis) and Johnson & Johnson in the United States District Court for the Southern District of New York alleging that Cordis’s sales of the CYPHER ™ and CYPHER SELECT ™ Stents made in the United States since 2005 willfully infringed four of Medinol's patents directed to the geometry of articulated stents. Medinol is seeking damages and attorneys’ fees. After trial in January 2014, the District Court dismissed the case, finding Medinol unreasonably delayed bringing its claims. In September 2014, the District Court denied a motion by Medinol to vacate the judgment and grant it a new trial. Medinol has appealed the decision to the United States Court of Appeals for the Federal Circuit. Cordis was divested in 2015, and the Company retained any liability that may result from this case. In November 2016, MedIdea, L.L.C. (MedIdea) filed a patent infringement lawsuit against DePuy Orthopaedics, Inc. in the United States District Court for the Northern District of Illinois alleging infringement by the ATTUNE ® Knee System. MedIdea alleges infringement of U.S. Patent Nos. 6,558,426; 8,273,132; 8,721,730 and 9,492,280 relating to posterior stabilized knee systems. Specifically, MedIdea alleges that the SOFCAM TM Contact feature of the ATTUNE ® posterior stabilized knee products infringes the patents-in-suit. MedIdea is seeking monetary damages and injunctive relief. In December 2016, Ethicon Endo-Surgery, Inc. and Ethicon Endo-Surgery, LLC (now known as Ethicon LLC) sued Covidien, Inc. in the United States District Court for the District of Massachusetts seeking a declaration that Covidien’s U.S. Patent Nos. 6,585,735 (the ’735 patent); 7,118,587; 7,473,253; 8,070,748 and 8,241,284 (the ’284 patent), are either invalid or not infringed by Ethicon’s ENSEAL ® X1 Large Jaw Tissue Sealer product. In April 2017, Covidien LP, Covidien Sales LLC, and Covidien AG answered and counterclaimed, denying the allegations, asserting willful infringement of the ’735 patent, the ’284 patent and U.S. Patent Nos. 8,323,310; 9,084,608; 9,241,759 and 9,113,882, and seeking damages and an injunction. Pharmaceutical In April 2016, MorphoSys AG, a German biotech company, filed a patent infringement lawsuit against Janssen Biotech, Inc. (JBI), Genmab U.S. Inc. and Genmab A/S (collectively, Genmab) in the United States District Court for the District of Delaware. MorphoSys alleges that JBI’s manufacture and sale of DARZALEX ® (daratumumab) willfully infringes MorphoSys’ U.S. Patent Nos. 8,263,746 and 9,200,061. MorphoSys is seeking money damages. JBI licenses patents and the commercial rights to DARZALEX ® from Genmab. Trial in the case is scheduled to commence in August 2018. In August 2016, Sandoz Ltd and Hexal AG (collectively, Sandoz) filed a lawsuit in the English High Court against G.D. Searle LLC (a Pfizer company) and Janssen Sciences Ireland UC (JSI) alleging that Searle’s supplementary protection certificate SPC/GB07/038 (SPC), which is exclusively licensed to JSI, is invalid and should be revoked. Janssen-Cilag Limited sells PREZISTA ® (darunavir) in the UK pursuant to this license. In October 2016, Searle and JSI counterclaimed against Sandoz for threatened infringement of the SPC based on statements of its plans to launch generic darunavir in the UK. Sandoz admitted that its generic darunavir product would infringe the SPC if it is found valid. Searle and JSI are seeking an order enjoining Sandoz from marketing its generic darunavir before the expiration of the SPC. Following a trial in April 2017, the Court entered a decision holding that the SPC is valid, and that a hearing will be scheduled regarding, among other things, Searle’s and JSI’s request for an injunction. REMICADE ® Related Cases U.S. Proceedings In September 2013, Janssen Biotech, Inc. (JBI) and NYU Langone Medical Center (NYU) received an Office Action from the United States Patent and Trademark Office (USPTO) rejecting the claims in U.S. Patent No. 6,284,471 relating to REMICADE ® (infliximab) (the ’471 patent) in a reexamination proceeding instituted by a third party. The ’471 patent expires in September 2018 and is co-owned by JBI and NYU, with NYU having granted JBI an exclusive license to NYU’s rights under the patent. Following several office actions by the patent examiner, including two further rejections, and responses by JBI, the USPTO issued a further action maintaining its rejection of the ’471 patent. JBI filed a notice of appeal to the USPTO’s Patent Trial and Appeal Board, which issued a decision in November 2016 upholding the examiner's rejection. JBI has filed an appeal to the United States Court of Appeals for the Federal Circuit. In August 2014, Celltrion Healthcare Co. Ltd. and Celltrion Inc. (together, Celltrion) filed an application with the U.S. Food and Drug Administration (FDA) for approval to make and sell its own infliximab biosimilar. In March 2015, JBI filed a lawsuit in the United States District Court for the District of Massachusetts against Celltrion and Hospira Healthcare Corporation (Hospira), which has exclusive U.S. marketing rights for Celltrion's infliximab biosimilar in the United States, seeking, among other things, a declaratory judgment that their biosimilar product infringes or potentially infringes several JBI patents, including the ’471 patent and U.S. Patent No. 7,598,083 (the ’083 patent). In August 2016, the District Court granted both Celltrion's and Hospira's motions for summary judgment of invalidity of the ’471 patent. JBI appealed those decisions to the United States Court of Appeals for the Federal Circuit. This case and the appeal of the reexamination of the ’471 patent have been designated companion cases and will be heard by the same panel of judges at the Federal Circuit. In June 2016, JBI filed two additional patent infringement lawsuits asserting the ’083 patent, one against Celltrion in the United States District Court for the District of Massachusetts and the other against HyClone Laboratories, Inc., the manufacturer of the cell culture media that Celltrion uses to make its biosimilar product, in the United States District Court for the District of Utah. Although the ’083 patent is already asserted in the existing lawsuit against Celltrion, the additional lawsuit expands the claims to include any use of the cell culture media made in the United States to manufacture Celltrion's biosimilar. This additional lawsuit against Celltrion has been consolidated with the existing lawsuit discussed above. Hospira has moved to dismiss all counts of the lawsuit related to the ’083 patent as to it. Celltrion has moved to dismiss all counts of the lawsuit related to the ’083 patent without prejudice for failure to join all the co-owners of the ’083 patent as plaintiffs. The trial has been postponed pending resolution of these motions. The FDA approved Celltrion’s infliximab biosimilar for sale in the United States in April 2016. Hospira's parent company, Pfizer Inc., launched Celltrion's infliximab biosimilar in the United States in late 2016. In April 2017, JBI received notice that the FDA approved a marketing application submitted by Samsung Bioepis Co. Ltd. for the sale of its infliximab biosimilar in the United States. Canadian Proceedings In March 2013, Hospira filed an impeachment proceeding in the Federal Court of Canada against The Kennedy Institute of Rheumatology (Kennedy) challenging the validity of a Canadian patent related to REMICADE ® (a Feldman patent), which is exclusively licensed to JBI. In October 2013, Kennedy, along with JBI, Janssen Inc. (Janssen) and Cilag GmbH International (both affiliates of JBI), filed a counterclaim for infringement against Celltrion and Hospira. The counterclaim alleges that the products described in Celltrion’s and Hospira’s marketing applications to Health Canada for their subsequent entry biologics (SEB) to REMICADE ® would infringe the Feldman patents owned by Kennedy. Janssen and Kennedy are seeking damages and an injunction against Hospira. A trial in this patent action concluded in October 2016, and closing arguments took place in January 2017. The parties are awaiting a decision. In January 2014, Health Canada approved Celltrion’s SEB to REMICADE ® , allowing Celltrion to market its infliximab biosimilar in Canada, regardless of the pending patent action. In June 2014, Health Canada approved Hospira’s SEB to REMICADE ® . In July 2014, Janssen filed a lawsuit in the Federal Court of Canada challenging the Canadian Minister of Health’s marketing approval (Notice of Compliance) for Hospira’s SEB because Hospira did not serve a Notice of Allegation on Janssen to address the patent listed by Janssen on the Patent Register. In March 2015, the parties entered a settlement agreement whereby Health Canada agreed to a Consent Judgment setting aside Hospira’s Notice of Compliance, subject to Health Canada's appeal, which was filed in June 2015. Nevertheless, Hospira began marketing an infliximab biosimilar as a distributor under Celltrion’s Notice of Compliance. In October 2016, the appeals court reversed the Consent Judgment. Janssen has filed an application for leave to appeal with the Supreme Court of Canada. Hospira continues to market and sell Celltrion's infliximab biosimilar in Canada. In Canada, if the REMICADE ® patent discussed above is found to be invalid following all appeals, it could not be relied upon to prevent the further introduction of infliximab biosimilars prior to the August 1, 2017 expiry date of the patent. Litigation Against Filers of Abbreviated New Drug Applications (ANDAs) The following summarizes lawsuits pending against generic companies that have filed Abbreviated New Drug Applications (ANDAs) with the FDA, or undertaken similar regulatory processes outside of the United States, seeking to market generic forms of products sold by various subsidiaries of Johnson & Johnson prior to expiration of the applicable patents covering those products. These ANDAs typically include allegations of non-infringement, invalidity and unenforceability of the applicable patents. In the event the subsidiaries are not successful in these actions, or the statutory 30-month stays of the ANDAs expire before the United States District Court rulings are obtained, the third-party companies involved will have the ability, upon approval of the FDA, to introduce generic versions of the products at issue to the market, resulting in the potential for substantial market share and revenue losses for those products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, subsidiaries may settle these actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents. The inter partes review (IPR) process with the United States Patent and Trademark Office (USPTO), created under the 2011 America Invents Act, is also being used by generic companies in conjunction with these ANDAs and lawsuits to challenge patents held by the Company’s subsidiaries. CONCERTA ® In October 2016, ALZA Corporation and Janssen Pharmaceuticals, Inc. (together, Janssen) initiated a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Amneal Pharmaceuticals of New York, LLC and Amneal Pharmaceuticals LLC (together, Amneal), who filed an ANDA seeking approval to market a generic version of CONCERTA ® before the expiration of United States Patent Nos. 8,163,798 and 9,144,549. Janssen is seeking an order enjoining Amneal from marketing its generic version of CONCERTA ® before the expiration of the patents. ZYTIGA ® In July 2015, Janssen Biotech, Inc. (JBI), Janssen Oncology, Inc. (Janssen Oncology) and Janssen Research & Development, LLC (collectively, Janssen) and BTG International Ltd. (BTG) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against a number of generic companies (and certain of their affiliates and/or suppliers) who filed ANDAs seeking approval to market a generic version of ZYTIGA ® before the expiration of United States Patent No. 8,822,438 (the ’438 patent). The generic companies currently include Actavis Laboratories, FL, Inc. (Actavis); Amneal Pharmaceuticals, LLC and Amneal Pharmaceuticals of New York, LLC (collectively, Amneal); Apotex Inc. and Apotex Corp. (collectively, Apotex); Citron Pharma LLC (Citron); Dr. Reddy’s Laboratories, Ltd. and Dr. Reddy’s Laboratories, Inc. (collectively, Dr. Reddy’s); Mylan Pharmaceuticals Inc. and Mylan Inc. (collectively, Mylan); Par Pharmaceuticals, Inc. and Par Pharmaceutical Companies, Inc. (collectively, Par); Sun Pharmaceutical Industries Ltd. and Sun Pharmaceuticals Industries, Inc. (collectively, Sun); Teva Pharmaceuticals USA, Inc. (Teva); Wockhardt Bio A.G.; Wockhardt USA LLC and Wockhardt Ltd. (collectively, Wockhardt); West-Ward Pharmaceutical Corp. (West-Ward) and Hikma Pharmaceuticals, LLC (Hikma). The Court has set a trial date of October 2017. Subsequently, Janssen and BTG initiated patent infringement lawsuits in the United States District Court for the District of New Jersey against Amerigen Pharmaceuticals Limited (Amerigen) in May 2016, and Glenmark Pharmaceuticals, Inc. in June 2016, each of whom filed an ANDA seeking approval to market its generic version of ZYTIGA ® before the expiration of the ’438 patent. In August 2015, Janssen and BTG filed an additional jurisdictional protective lawsuit against the Mylan defendants in the United States District Court for the Northern District of West Virginia, which has been stayed. In each of the above lawsuits, Janssen is seeking an order enjoining the defendants from marketing their generic versions of ZYTIGA ® before the expiration of the ’438 patent. Several generic companies including Amerigen, Argentum Pharmaceuticals LLC (Argentum), Mylan, Wockhardt, Actavis, Amneal, Dr. Reddy’s, Sun, Teva, West-Ward and Hikma have filed Petitions for Inter Partes Review (IPR) with the USPTO, seeking to invalidate the ’438 patent. A final written decision in the IPRs filed by Amerigen and Argentum, which were joined, is expected by May 2017. Final written decisions in the IPRs filed by Mylan, Actavis, Amneal, Dr. Reddy’s, Sun, Teva, West-Ward and Hikma, which were joined, and in the Wockhardt IPR, are expected by January 2018. COMPLERA ® In August and September 2015, Janssen Pharmaceutica NV and Janssen Sciences Ireland UC (collectively, Janssen) and Gilead Sciences, Inc. and Gilead Sciences Ireland UC (collectively, Gilead) initiated patent infringement lawsuits in the United States District Courts for the District of Delaware and the District of West Virginia, respectively, against Mylan, Inc. and Mylan Pharmaceuticals, Inc. (collectively, Mylan), who filed an ANDA seeking approval to market a generic version of COMPLERA ® before the expiration of U.S. Patent Nos. 8,841,310, 7,125,879 and 8,101,629. The West Virginia lawsuit has been stayed, with a conditional trial date in February 2018, in accordance with the schedule in the first-filed Delaware lawsuit. In the Delaware lawsuit, Janssen and Gilead amended their complaint to add claims for patent infringement with respect to U.S. Patent Nos. 8,080,551; 7,399,856; 7,563,922; 8,101,752 and 8,618,291. A trial in the Delaware action has been scheduled for February 2018. In each of these lawsuits, Janssen is seeking an order enjoining the defendants from marketing their generic versions of COMPLERA ® before the expiration of the relevant patents. XARELTO ® B eginning in October 2015, Janssen Pharmaceuticals, Inc. (JPI) and Bayer Pharma AG and Bayer Intellectual Property GmbH (together, Bayer) filed patent infringement lawsuits in the United States District Court for the District of Delaware against a number of generic companies who filed ANDAs seeking approval to market generic versions of XARELTO ® before expiration of Bayer’s U.S. Patent Nos. 7,157,456 , 7,585,860 and 7,592,339 relating to XARELTO ® . JPI is the exclusive licensee of the asserted patents. The following generic companies are named defendants: Aurobindo Pharma Limited and Aurobindo Pharma USA, Inc. (together, Aurobindo), Breckenridge Pharmaceutical, Inc., Invagen Pharmaceuticals Inc., Micro Labs USA Inc. and Micro Labs Ltd. Mylan Pharmaceuticals Inc., Prinston Pharmaceutical, Inc., Sigmapharm Laboratories, LLC, Torrent Pharmaceuticals, Limited and Torrent Pharma Inc. Trial is scheduled for March 2018. In April 2017, JPI, Bayer Intellectual Property GmbH and Bayer AG filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Taro Pharmaceutical Industries Ltd. and Taro Pharmaceuticals U.S.A., Inc., who filed an ANDA seeking approval to market a generic version of XARELTO ® before expiration of Bayer’s U.S. Patent No. 9,539,218 relating to XARELTO ® (the ’218 patent). In April 2017, JPI, Bayer Intellectual Property GmbH and Bayer AG filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Aurobindo, who filed an ANDA seeking approval to market a generic version of XARELTO ® before expiration of the ’218 patent. In each of these lawsuits, JPI is seeking an order enjoining the defendants from marketing their generic versions of XARELTO ® before the expiration of the relevant patents. RISPERDAL ® CONSTA ® On November 30, 2016, the United States Patent and Trademark Office (USPTO) instituted an Inter Partes Review filed by Luye Pharma Group Ltd., Luye Pharma (USA) Ltd., Sandong Luye Pharmaceutical Co., Ltd. and Nanjing Luye Pharmaceutical Co., Ltd., seeking to invalidate U.S. Patent No. 6,667,061 relating to RISPERDAL CONSTA ® . Janssen Pharmaceuticals, Inc. markets RISPERDAL CONSTA ® pursuant to a license from Alkermes Pharma Ireland Ltd. A decision by the USPTO is expected in November 2017. GOVERNMENT PROCEEDINGS Like other companies in the pharmaceutical and medical devices industries, Johnson & Johnson and certain of its subsidiaries are subject to extensive regulation by national, state and local government agencies in the United States and other countries in which they operate. As a result, interaction with government agencies is ongoing. The most significant litigation brought by, and investigations conducted by, government agencies are listed below. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from government investigations or litigation. Average Wholesale Price (AWP) Litigation Johnson & Johnson and several of its pharmaceutical subsidiaries (the J&J AWP Defendants), along with numerous other pharmaceutical companies, were named as defendants in a series of lawsuits in state and federal courts involving allegations that the pricing and marketing of certain pharmaceutical products amounted to fraudulent and otherwise actionable conduct because, among other things, the companies allegedly reported an inflated Average Wholesale Price (AWP) for the drugs at issue. Payors alleged that they used those AWPs in calculating provider r

Restructuring

Restructuring	3 Months Ended
	Apr. 02, 2017
Restructuring and Related Activities [Abstract]
Restructuring	RESTRUCTURING The Company announced restructuring actions in its Medical Devices segment to better serve the needs of patients and customers in today’s evolving healthcare marketplace. The Company is undertaking actions to strengthen its go-to-market model, accelerate the pace of innovation, further prioritize key platforms and geographies, and streamline operations while maintaining high quality standards. The Company estimates that, in connection with its plans, it will record pre-tax restructuring and other charges of approximately $2.0 billion to $2.4 billion . In the fiscal first quarter of 2017, the Company recorded a pre-tax charge of $161 million , of which $4 million was included in cost of products sold and $72 million was included in other (income) expense. See table below for additional details. Total project costs of $1.4 billion have been recorded since the restructuring has been announced. Additionally, as part of the plan, the Company expects that the restructuring actions will result in position eliminations of approximately 4 to 6 percent of the Medical Devices segment’s global workforce over the next 18 months , subject to any consultation procedures in countries, where required. Approximately 1,600 positions have been eliminated since the restructuring has been announced. The Company estimates that approximately one half of the cumulative pre-tax costs will result in cash outlays, including approximately $500 million of employee severance. Approximately one half of the cumulative pre-tax costs are non-cash, relating primarily to facility rationalization, inventory write-offs and intangible asset write-offs. The following table summarizes the severance related reserves and the associated spending under this initiative through the fiscal first quarter of 2017: (Dollars in Millions) Severance Asset Write-offs Other** Total Reserve balance, January 1, 2017 $ 380 — 1 381 Current year activity: Charges — 37 124 161 Cash payments (25 ) — (118 ) (143 ) Settled non cash — (37 ) — (37 ) Reserve balance, April 2, 2017* $ 355 — 7 362 *Cash outlays for severance are expected to be substantially paid out over the next 2 years in accordance with the Company's plans and local laws. **Other includes project expense such as salaries for employees supporting the initiative and consulting expenses.

Fair Value Measurements (Polici

Fair Value Measurements (Policies)	3 Months Ended
	Apr. 02, 2017
Fair Value Disclosures [Abstract]
Cash and Cash Equivalents, Policy	The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available for current operations and are classified as cash equivalents and current marketable securities.

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Apr. 02, 2017
Inventory Disclosure [Abstract]
Summary of Inventories	(Dollars in Millions) April 2, 2017 January 1, 2017 Raw materials and supplies $ 1,046 952 Goods in process 2,121 2,185 Finished goods 5,711 5,007 Total inventories $ 8,878 8,144

Intangible Assets and Goodwill

Intangible Assets and Goodwill (Tables)	3 Months Ended
	Apr. 02, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill	(Dollars in Millions) April 2, 2017 January 1, 2017 Intangible assets with definite lives: Patents and trademarks — gross $ 11,311 10,521 Less accumulated amortization 5,226 5,076 Patents and trademarks — net 6,085 5,445 Customer relationships and other intangibles — gross 19,653 17,615 Less accumulated amortization 6,741 6,515 Customer relationships and other intangibles — net 12,912 11,100 Intangible assets with indefinite lives: Trademarks 6,957 6,888 Purchased in-process research and development 3,512 3,443 Total intangible assets with indefinite lives 10,469 10,331 Total intangible assets — net $ 29,466 26,876
Goodwill	Goodwill as of April 2, 2017 was allocated by segment of business as follows: (Dollars in Millions) Consumer Pharm Med Devices Total Goodwill, net at January 1, 2017 $ 8,263 2,840 11,702 22,805 Goodwill, related to acquisitions 10 — 2,040 2,050 Currency translation/Other 71 14 (96 ) (1) (11 ) Goodwill, net at April 2, 2017 $ 8,344 2,854 13,646 24,844 (1) Net of $106 million classified as held for sale, reported in other assets on the Consolidated Balance Sheet, related to the divestiture of the Codman Neurosurgery business which was pending as of April 2, 2017.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Apr. 02, 2017
Fair Value Disclosures [Abstract]
Summary of Derivative Activity	The following table is a summary of the activity related to derivatives designated as cash flow hedges for the fiscal first quarters in 2017 and 2016 : Gain/(Loss) Recognized In Accumulated OCI (1) Gain/(Loss) Reclassified From Accumulated OCI Into Income (1) Gain/(Loss) Recognized In Other Income/Expense (2) (Dollars in Millions) Fiscal Three Months Ended Cash Flow Hedges By Income Statement Caption April 2, 2017 April 3, 2016 April 2, 2017 April 3, 2016 April 2, 2017 April 3, 2016 Sales to customers (3) $ (13 ) — (33 ) (18 ) — — Cost of products sold (3) (97 ) (44 ) (31 ) (21 ) (17 ) (4 ) Research and development expense (3) (109 ) (107 ) (102 ) (95 ) 5 — Interest (income)/Interest expense, net (4) 28 12 22 8 — — Other (income) expense, net (3) (5) (33 ) (52 ) (35 ) 4 1 (3 ) Total $ (224 ) (191 ) (179 ) (122 ) (11 ) (7 ) All amounts shown in the table above are net of tax. (1) Effective portion (2) Ineffective portion (3) Forward foreign exchange contracts (4) Cross currency interest rate swaps (5) Includes equity collar contracts
Financial Assets and Liabilities at Fair Value	The Company’s significant financial assets and liabilities measured at fair value as of April 2, 2017 and January 1, 2017 were as follows: April 2, 2017 January 1, 2017 (Dollars in Millions) Level 1 Level 2 Level 3 Total Total (1) Derivatives designated as hedging instruments: Assets: Forward foreign exchange contracts (7) $ — 291 — 291 747 Interest rate contracts (2)(4)(7) — 29 — 29 31 Total — 320 — 320 778 Liabilities: Forward foreign exchange contracts (8) — 576 — 576 723 Interest rate contracts (3)(4)(8) — 345 — 345 382 Equity collar contracts (8) — 63 — 63 57 Total — 984 — 984 1,162 Derivatives not designated as hedging instruments: Assets: Forward foreign exchange contracts (7) — 26 — 26 34 Liabilities: Forward foreign exchange contracts (8) — 62 — 62 57 Available For Sale Other Investments: Equity investments (5) 1,008 — — 1,008 1,209 Debt securities (6) $ — 26,808 — 26,808 12,087 (1) 2016 assets and liabilities are all classified as Level 2 with the exception of equity investments of $1,209 million , which are classified as Level 1. (2) Includes $21 million and $23 million of non-current other assets for April 2, 2017 and January 1, 2017, respectively. (3) Includes $345 million and $382 million of non-current other liabilities for April 2, 2017 and January 1, 2017, respectively. (4) Includes cross currency interest rate swaps and interest rate swaps. (5) Classified as non-current other assets with the exception of $246 million of current other assets for April 2, 2017 . The original cost of the equity investments were $471 million and $520 million as of April 2, 2017 and January 1, 2017, respectively. The unrealized gains were $607 million and $757 million as of April 2, 2017 and January 1, 2017, respectively. The unrealized losses were $70 million and $68 million as of April 2, 2017 and January 1, 2017, respectively. (6) Classified as cash equivalents and current marketable securities. (7) Classified as other current assets. (8) Classified as accounts payable.
Marketable Securities	The Company's cash, cash equivalents and current marketable securities as of April 2, 2017 comprised: April 2, 2017 (Dollars in Millions) Carrying Amount Unrecognized Gain Unrecognized Loss Estimated Fair Value Cash & Cash Equivalents Current Marketable Securities Cash $ 2,205 — — 2,205 2,205 U.S. Gov't Securities (1) 1,899 — — 1,899 — 1,899 Other Sovereign Securities (1) 90 — — 90 — 90 U.S. Reverse repurchase agreements 4,726 — — 4,726 4,726 — Other Reverse repurchase agreements 214 — — 214 214 Corporate debt securities (1) 80 — — 80 — 80 Money market funds 1,923 — — 1,923 1,923 Time deposits (1) 1,152 — — 1,152 1,152 Subtotal 12,289 — — 12,289 10,220 2,069 Unrealized Gain Unrealized Loss Gov't securities 24,903 6 (42 ) 24,867 10,689 14,178 Other Sovereign Securities 91 — — 91 — 91 Corporate debt securities 1,857 2 (9 ) 1,850 — 1,850 Equity investments 23 223 — 246 — 246 Subtotal Available for Sale (2) $ 26,874 231 (51 ) 27,054 10,689 16,365 Total cash, cash equivalents and current marketable securities 20,909 18,434 (1) Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. (2) Available for sale securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.
Schedule of Available for Sale Securities Maturities	The contractual maturities of the available for sale securities at April 2, 2017 are as follows: (Dollars in Millions) Cost Basis Fair Value Due within one year $ 16,571 16,568 Due after one year through five years 10,280 10,240 Due after five years through ten years — — Total debt securities $ 26,851 26,808
Financial Liabilities not Measured at Fair Value	Financial Instruments not measured at Fair Value: The following financial liabilities are held at carrying amount on the consolidated balance sheet as of April 2, 2017 : (Dollars in Millions) Carrying Amount Estimated Fair Value Financial Liabilities Current Debt $ 5,355 5,355 Non-Current Debt 5.15% Debentures due 2018 899 942 1.65% Notes due 2018 601 605 4.75% Notes due 2019 (1B Euro 1.0725) 1,069 1,204 1.875% Notes due 2019 501 505 0.89% Notes due 2019 300 301 1.125% Notes due 2019 699 696 3% Zero Coupon Convertible Subordinated Debentures due in 2020 83 142 2.95% Debentures due 2020 546 566 3.55% Notes due 2021 447 473 2.45% Notes due 2021 349 355 1.65% Notes due 2021 997 986 0.250% Notes due 2022 (1B Euro 1.0725) 1,069 1,072 2.25% Notes due 2022 994 995 6.73% Debentures due 2023 249 310 3.375% Notes due 2023 807 851 2.05% Notes due 2023 497 486 0.650% Notes due 2024 (750MM Euro 1.0725) 799 805 5.50% Notes due 2024 (500 MM GBP 1.2474) 617 804 2.45% Notes due 2026 1,989 1,915 2.95% Notes due 2027 995 996 1.150% Notes due 2028 (750MM Euro 1.0725) 796 805 6.95% Notes due 2029 296 401 4.95% Debentures due 2033 498 589 4.375% Notes due 2033 857 951 1.650% Notes due 2035 (1.5B Euro 1.0725) 1,590 1,646 3.55% Notes due 2036 987 981 5.95% Notes due 2037 990 1,290 3.625% Notes due 2037 1,485 1,473 5.85% Debentures due 2038 695 908 4.50% Debentures due 2040 537 592 4.85% Notes due 2041 296 345 4.50% Notes due 2043 495 548 3.70% Notes due 2046 1,970 1,929 3.75% Notes due 2047 990 982 Other 26 26 Total Non-Current Debt $ 27,015 28,475

Pensions and Other Postretire24

Pensions and Other Postretirement Benefits (Tables)	3 Months Ended
	Apr. 02, 2017
Compensation and Retirement Disclosure [Abstract]
Components of Net Periodic Benefit Cost	Net periodic benefit cost for the Company’s defined benefit retirement plans and other benefit plans for the fiscal first quarters of 2017 and 2016 include the following components: Fiscal First Quarters Ended Retirement Plans Other Benefit Plans (Dollars in Millions) April 2, 2017 April 3, 2016 April 2, 2017 April 3, 2016 Service cost $ 251 226 61 55 Interest cost 230 233 39 40 Expected return on plan assets (505 ) (492 ) (2 ) (2 ) Amortization of prior service cost/(credit) — 1 (7 ) (8 ) Recognized actuarial losses 152 124 34 34 Curtailments and settlements — 1 — — Net periodic benefit cost $ 128 93 125 119

Accumulated Other Comprehensi25

Accumulated Other Comprehensive Income (Tables)	3 Months Ended
	Apr. 02, 2017
Equity [Abstract]
Components of Accumulated Other Comprehensive Income	Components of other comprehensive income (loss) consist of the following: Foreign Gain/(Loss) Employee Gain/(Loss) Total Accumulated Currency On Benefit On Derivatives Other Comprehensive (Dollars in Millions) Translation Securities Plans & Hedges Income (Loss) January 1, 2017 $ (9,047 ) 411 (5,980 ) (285 ) (14,901 ) Net change 395 (90 ) 119 (45 ) 379 April 2, 2017 $ (8,652 ) 321 (5,861 ) (330 ) (14,522 )

Earnings Per Share (Tables)

Earnings Per Share (Tables)	3 Months Ended
	Apr. 02, 2017
Earnings Per Share [Abstract]
Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share	The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal first quarters ended April 2, 2017 and April 3, 2016 : Fiscal First Quarters Ended (Shares in Millions) April 2, 2017 April 3, 2016 * Basic net earnings per share $ 1.63 1.62 Average shares outstanding — basic 2,706.6 2,757.2 Potential shares exercisable under stock option plans 141.2 145.7 Less: shares which could be repurchased under treasury stock method (94.6 ) (101.1 ) Convertible debt shares 1.3 2.0 Average shares outstanding — diluted 2,754.5 2,803.8 Diluted net earnings per share $ 1.61 1.59 *The fiscal first quarter of 2016 has been recast to reflect the adoption of ASU 2016-09. See Note 1 to the Consolidated Financial Statements in the Annual Report on Form 10-K for the fiscal year ended January 1, 2017 for more detailed information regarding the adoption of ASU 2016-09.

Segments of Business and Geog27

Segments of Business and Geographic Areas (Tables)	3 Months Ended
	Apr. 02, 2017
Segment Reporting [Abstract]
Sales By Segment Of Business	Fiscal First Quarters Ended (Dollars in Millions) April 2, April 3, Percent Change Consumer United States $ 1,414 1,358 4.1 % International 1,814 1,837 (1.3 ) Total 3,228 3,195 1.0 Pharmaceutical United States 4,872 4,937 (1.3 ) International 3,373 3,241 4.1 Total 8,245 8,178 0.8 Medical Devices United States 3,092 3,026 2.2 International 3,201 3,083 3.8 Total 6,293 6,109 3.0 Worldwide United States 9,378 9,321 0.6 International 8,388 8,161 2.8 Total $ 17,766 17,482 1.6 %
Operating Profit by Segment of Business	Fiscal First Quarters Ended (Dollars in Millions) April 2, April 3, Percent Change Consumer $ 596 566 5.3 % Pharmaceutical (1) 3,663 3,344 9.5 Medical Devices (2) 1,563 1,576 (0.8 ) Segments operating profit 5,822 5,486 6.1 Less: Expense not allocated to segments (3) 247 192 Worldwide income before tax $ 5,575 5,294 5.3 % (1) Includes a gain of $0.2 billion and $0.1 billion in the fiscal first quarters of 2017 and 2016, respectively, related to the sale of certain investments in equity securities held by Johnson & Johnson Innovation - JJDC, Inc. Includes a positive adjustment of $0.2 billion to previous reserve estimates in the fiscal first quarter of 2016. (2) Includes a restructuring related charge of $161 million and $137 million in the fiscal first quarter of 2017 and 2016, respectively. Includes litigation expense of $106 million in the fiscal first quarter of 2016. (3) Amounts not allocated to segments include interest income/expense and general corporate income/expense.
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas	Fiscal First Quarters Ended (Dollars in Millions) April 2, 2017 April 3, 2016 Percent Change United States $ 9,378 9,321 0.6 % Europe 3,858 3,847 0.3 Western Hemisphere, excluding U.S. 1,454 1,331 9.2 Asia-Pacific, Africa 3,076 2,983 3.1 Total $ 17,766 17,482 1.6 %

Restructuring (Tables)

Restructuring (Tables)	3 Months Ended
	Apr. 02, 2017
Restructuring and Related Activities [Abstract]
Schedule of Restructuring Reserve	The following table summarizes the severance related reserves and the associated spending under this initiative through the fiscal first quarter of 2017: (Dollars in Millions) Severance Asset Write-offs Other** Total Reserve balance, January 1, 2017 $ 380 — 1 381 Current year activity: Charges — 37 124 161 Cash payments (25 ) — (118 ) (143 ) Settled non cash — (37 ) — (37 ) Reserve balance, April 2, 2017* $ 355 — 7 362 *Cash outlays for severance are expected to be substantially paid out over the next 2 years in accordance with the Company's plans and local laws. **Other includes project expense such as salaries for employees supporting the initiative and consulting expenses.

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Apr. 02, 2017	Jan. 01, 2017
Summary of Inventories
Raw materials and supplies	$ 1,046	$ 952
Goods in process	2,121	2,185
Finished goods	5,711	5,007
Total inventories	8,878	$ 8,144
Inventories [Member] | Codman Neurosurgery [Member]
Inventory [Line Items]
Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent	$ 65

Intangible Assets and Goodwil30

Intangible Assets and Goodwill (Details) - USD ($) $ in Millions	Apr. 02, 2017	Jan. 01, 2017
Intangible assets with indefinite lives:
Indefinite-Lived Intangible Assets	$ 10,469	$ 10,331
Total intangible assets - net	29,466	26,876
Trademarks
Intangible assets with indefinite lives:
Indefinite-Lived Intangible Assets	6,957	6,888
Purchased In-Process Research And Development
Intangible assets with indefinite lives:
Indefinite-Lived Intangible Assets	3,512	3,443
Patents And Trademarks
Intangible assets with definite lives:
Finite-Lived Intangible Assets, Gross	11,311	10,521
Less accumulated amortization	5,226	5,076
Finite-Lived Intangible Assets, Net	6,085	5,445
Customer relationships and other intangible assets
Intangible assets with definite lives:
Finite-Lived Intangible Assets, Gross	19,653	17,615
Less accumulated amortization	6,741	6,515
Finite-Lived Intangible Assets, Net	$ 12,912	$ 11,100

Goodwill By Segment (Details)

Goodwill By Segment (Details) $ in Millions	3 Months Ended
	Apr. 02, 2017USD ($)
Goodwill [Roll Forward]
Goodwill Beginning of Period	$ 22,805
Goodwill, related to acquisitions	2,050
Currency translation/Other	(11)
Goodwill End of Period	24,844
Consumer
Goodwill [Roll Forward]
Goodwill Beginning of Period	8,263
Goodwill, related to acquisitions	10
Currency translation/Other	71
Goodwill End of Period	8,344
Pharmaceutical
Goodwill [Roll Forward]
Goodwill Beginning of Period	2,840
Goodwill, related to acquisitions	0
Currency translation/Other	14
Goodwill End of Period	2,854
Medical Devices
Goodwill [Roll Forward]
Goodwill Beginning of Period	11,702
Goodwill, related to acquisitions	2,040
Currency translation/Other	(96)
Goodwill End of Period	$ 13,646

Intangible Assets and Goodwil32

Intangible Assets and Goodwill - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 02, 2017	Apr. 03, 2016	Jan. 01, 2017
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	$ 1,500
Finite-Lived Intangible Assets, Amortization Expense, Year Two	1,500
Finite-Lived Intangible Assets, Amortization Expense, Year Three	1,500
Finite-Lived Intangible Assets, Amortization Expense, Year Four	1,500
Finite-Lived Intangible Assets, Amortization Expense, Year Five	1,500
Intangible Assets and Goodwill (Textuals)
Amortization expense of amortizable intangible assets	329	$ 282
Goodwill	$ 24,844		$ 22,805
Patents And Trademarks
Intangible Assets and Goodwill (Textuals)
Finite-Lived Intangible Assets, Weighted-Average Useful Life	19 years
Customer relationships and other intangible assets
Intangible Assets and Goodwill (Textuals)
Finite-Lived Intangible Assets, Weighted-Average Useful Life	23 years
Pharmaceutical
Intangible Assets and Goodwill (Textuals)
Goodwill	$ 2,854		2,840
Medical Devices [Member]
Intangible Assets and Goodwill (Textuals)
Goodwill	13,646		$ 11,702
AMO [Member] | Medical Devices [Member]
Intangible Assets and Goodwill (Textuals)
Finite-lived Intangible Assets Acquired	2,300
Goodwill	1,900
Goodwill [Member] | Codman Neurosurgery [Member]
Finite-Lived Intangible Assets [Line Items]
Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent	$ 106

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details) - USD ($) $ in Millions	3 Months Ended			12 Months Ended
	Apr. 02, 2017	Jan. 01, 2017	Apr. 03, 2016	Apr. 02, 2017
Derivative [Line Items]
Foreign currency translation	$ 395		$ 879
Accumulated other comprehensive income on derivatives, after tax	$ 330			$ 330
Reclassification of foreign exchange contracts into earnings, period	next 12 months
Maximum length of time for hedge exposure	18 months
Other income/(expense), net, related to foreign exchange contracts, non hedging	$ (29)		$ (5)
Excess fair value over carrying value of cash and cash equivalents		$ 200
Weighted average interest rate on non-current debt	3.28%			3.28%
Excess of the estimated fair value over the carrying value of debt		1,600
Foreign exchange contracts
Derivative [Line Items]
Derivative notional amounts outstanding	$ 33,100	36,000		$ 33,100
Cross currency interest rate swaps
Derivative [Line Items]
Derivative notional amounts outstanding	2,300	2,300		2,300
Interest Rate Contract
Derivative [Line Items]
Derivative notional amounts outstanding	1,800	1,800		1,800
Equity Contract
Derivative [Line Items]
Derivative notional amounts outstanding	200	$ 300		200
Other Comprehensive Income (Loss) [Member]
Derivative [Line Items]
Foreign currency translation	$ (110)			$ 265

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Derivative Activity (Details) - Designated as Hedging Instrument - USD ($) $ in Millions	3 Months Ended
	Apr. 02, 2017	Apr. 03, 2016
Summary of designated derivatives
Gain/ (Loss) recognized in Accumulated OCI	$ (224)	$ (191)
Gain/ (Loss) reclassified from Accumulated OCI into income	(179)	(122)
Gain/ (Loss) recognized in Other income/expense	(11)	(7)
Foreign exchange contracts | Sales to customers
Summary of designated derivatives
Gain/ (Loss) recognized in Accumulated OCI	(13)	0
Gain/ (Loss) reclassified from Accumulated OCI into income	(33)	(18)
Gain/ (Loss) recognized in Other income/expense	0	0
Foreign exchange contracts | Cost of products sold
Summary of designated derivatives
Gain/ (Loss) recognized in Accumulated OCI	(97)	(44)
Gain/ (Loss) reclassified from Accumulated OCI into income	(31)	(21)
Gain/ (Loss) recognized in Other income/expense	(17)	(4)
Foreign exchange contracts | Research and development expense
Summary of designated derivatives
Gain/ (Loss) recognized in Accumulated OCI	(109)	(107)
Gain/ (Loss) reclassified from Accumulated OCI into income	(102)	(95)
Gain/ (Loss) recognized in Other income/expense	5	0
Foreign exchange contracts | Other (income) expense, net
Summary of designated derivatives
Gain/ (Loss) recognized in Accumulated OCI	(33)	(52)
Gain/ (Loss) reclassified from Accumulated OCI into income	(35)	4
Gain/ (Loss) recognized in Other income/expense	1	(3)
Cross currency interest rate swaps | Interest (income)/Interest expense, net
Summary of designated derivatives
Gain/ (Loss) recognized in Accumulated OCI	28	12
Gain/ (Loss) reclassified from Accumulated OCI into income	22	8
Gain/ (Loss) recognized in Other income/expense	$ 0	$ 0

Fair Value Measurements - Finan

Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details) - USD ($) $ in Millions	Apr. 02, 2017	Jan. 01, 2017
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	$ 320
Derivatives designated as hedging instruments : Liabilities	984
Available-for-sale Securities, Equity Securities	1,008	$ 1,209
Available-for-sale Securities	26,808	12,087
Quoted prices in active markets for identical assets and liabilities Level 1
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Available-for-sale Securities, Equity Securities	1,008	1,209
Available-for-sale Securities	0
Significant other observable inputs Level 2
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	320	778
Derivatives designated as hedging instruments : Liabilities	984	1,162
Available-for-sale Securities, Equity Securities	0
Available-for-sale Securities	26,808
Significant unobservable inputs Level 3
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Available-for-sale Securities, Equity Securities	0
Available-for-sale Securities	0
Interest Rate Contract
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	1,800	1,800
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	29
Derivatives designated as hedging instruments : Liabilities	345
Derivative Assets, Noncurrent	21	23
Derivative Liabilities, Noncurrent	345	382
Interest Rate Contract | Quoted prices in active markets for identical assets and liabilities Level 1
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Interest Rate Contract | Significant other observable inputs Level 2
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	29	31
Derivatives designated as hedging instruments : Liabilities	345	382
Interest Rate Contract | Significant unobservable inputs Level 3
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Equity Contract
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	200	300
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Liabilities	63
Equity Contract | Quoted prices in active markets for identical assets and liabilities Level 1
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Liabilities	0
Equity Contract | Significant other observable inputs Level 2
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Liabilities	63	57
Equity Contract | Significant unobservable inputs Level 3
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Liabilities	0
Foreign exchange contracts
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	33,100	36,000
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	291
Derivatives designated as hedging instruments : Liabilities	576
Derivatives not designated as hedging instruments : Assets	26
Derivatives not designated as hedging instruments : Liabilities	62
Foreign exchange contracts | Quoted prices in active markets for identical assets and liabilities Level 1
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Derivatives not designated as hedging instruments : Assets	0
Derivatives not designated as hedging instruments : Liabilities	0
Foreign exchange contracts | Significant other observable inputs Level 2
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	291	747
Derivatives designated as hedging instruments : Liabilities	576	723
Derivatives not designated as hedging instruments : Assets	26	34
Derivatives not designated as hedging instruments : Liabilities	62	57
Foreign exchange contracts | Significant unobservable inputs Level 3
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Derivatives not designated as hedging instruments : Assets	0
Derivatives not designated as hedging instruments : Liabilities	0
Cross Currency Interest Rate Contract [Member]
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	2,300	2,300
Equity Securities [Member]
Financial assets and liabilities at fair value
Available-for-sale Securities, Equity Securities	471	520
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	607	757
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	70	$ 68
Other Current Assets [Member] | Equity Securities [Member]
Financial assets and liabilities at fair value
Available-for-sale Securities, Equity Securities	$ 246

Fair Value Measurements - Cash

Fair Value Measurements - Cash, Cash Equivalents and Marketable Securities (Details) - USD ($) $ in Millions	Apr. 02, 2017	Jan. 01, 2017	Apr. 03, 2016	Jan. 03, 2016
Available-for-sale Securities [Abstract]
Available-for-sale Securities - Estimated Fair Value	$ 26,808	$ 12,087
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents	20,909	18,972	$ 13,861	$ 13,732
Marketable securities	18,434	$ 22,935
Held-to-maturity Securities
Held-to-maturity Securities [Abstract]
Held-to-maturity Securities - Carrying Amount	12,289
Held-to-maturity Securities, Accumulated Unrecognized Holding Gain	0
Held-to-maturity Securities, Accumulated Unrecognized Holding Loss	0
Held-to-maturity Securities - Estimated Fair Value	12,289
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents	10,220
Marketable securities	2,069
Held-to-maturity Securities | Cash
Held-to-maturity Securities [Abstract]
Held-to-maturity Securities - Carrying Amount	2,205
Held-to-maturity Securities, Accumulated Unrecognized Holding Gain	0
Held-to-maturity Securities, Accumulated Unrecognized Holding Loss	0
Held-to-maturity Securities - Estimated Fair Value	2,205
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents	2,205
Held-to-maturity Securities | U.S. Gov't Securities(1)
Held-to-maturity Securities [Abstract]
Held-to-maturity Securities - Carrying Amount	1,899
Held-to-maturity Securities, Accumulated Unrecognized Holding Gain	0
Held-to-maturity Securities, Accumulated Unrecognized Holding Loss	0
Held-to-maturity Securities - Estimated Fair Value	1,899
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents	0
Marketable securities	1,899
Held-to-maturity Securities | Other Sovereign Securities(1)
Held-to-maturity Securities [Abstract]
Held-to-maturity Securities - Carrying Amount	90
Held-to-maturity Securities, Accumulated Unrecognized Holding Gain	0
Held-to-maturity Securities, Accumulated Unrecognized Holding Loss	0
Held-to-maturity Securities - Estimated Fair Value	90
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents	0
Marketable securities	90
Held-to-maturity Securities | U.S. Reverse repurchase agreements
Held-to-maturity Securities [Abstract]
Held-to-maturity Securities - Carrying Amount	4,726
Held-to-maturity Securities, Accumulated Unrecognized Holding Gain	0
Held-to-maturity Securities, Accumulated Unrecognized Holding Loss	0
Held-to-maturity Securities - Estimated Fair Value	4,726
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents	4,726
Marketable securities	0
Held-to-maturity Securities | Other Reverse repurchase agreements
Held-to-maturity Securities [Abstract]
Held-to-maturity Securities - Carrying Amount	214
Held-to-maturity Securities, Accumulated Unrecognized Holding Gain	0
Held-to-maturity Securities, Accumulated Unrecognized Holding Loss	0
Held-to-maturity Securities - Estimated Fair Value	214
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents	214
Held-to-maturity Securities | Corporate debt securities(1)
Held-to-maturity Securities [Abstract]
Held-to-maturity Securities - Carrying Amount	80
Held-to-maturity Securities, Accumulated Unrecognized Holding Gain	0
Held-to-maturity Securities, Accumulated Unrecognized Holding Loss	0
Held-to-maturity Securities - Estimated Fair Value	80
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents	0
Marketable securities	80
Held-to-maturity Securities | Money market funds
Held-to-maturity Securities [Abstract]
Held-to-maturity Securities - Carrying Amount	1,923
Held-to-maturity Securities, Accumulated Unrecognized Holding Gain	0
Held-to-maturity Securities, Accumulated Unrecognized Holding Loss	0
Held-to-maturity Securities - Estimated Fair Value	1,923
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents	1,923
Held-to-maturity Securities | Time deposits(1)
Held-to-maturity Securities [Abstract]
Held-to-maturity Securities - Carrying Amount	1,152
Held-to-maturity Securities, Accumulated Unrecognized Holding Gain	0
Held-to-maturity Securities, Accumulated Unrecognized Holding Loss	0
Held-to-maturity Securities - Estimated Fair Value	1,152
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents	1,152
Available-for-sale Securities
Available-for-sale Securities [Abstract]
Available-for-sale Securities - Carrying Amount	26,874
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	231
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	(51)
Available-for-sale Securities - Estimated Fair Value	27,054
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents	10,689
Marketable securities	16,365
Available-for-sale Securities | U.S. Gov't Securities(1)
Available-for-sale Securities [Abstract]
Available-for-sale Securities - Carrying Amount	24,903
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	6
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	(42)
Available-for-sale Securities - Estimated Fair Value	24,867
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents	10,689
Marketable securities	14,178
Available-for-sale Securities | Other Sovereign Securities(1)
Available-for-sale Securities [Abstract]
Available-for-sale Securities - Carrying Amount	91
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	0
Available-for-sale Securities - Estimated Fair Value	91
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents	0
Marketable securities	91
Available-for-sale Securities | Corporate debt securities(1)
Available-for-sale Securities [Abstract]
Available-for-sale Securities - Carrying Amount	1,857
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	2
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	(9)
Available-for-sale Securities - Estimated Fair Value	1,850
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents	0
Marketable securities	1,850
Available-for-sale Securities | Equity investments
Available-for-sale Securities [Abstract]
Available-for-sale Securities - Carrying Amount	23
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	223
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	0
Available-for-sale Securities - Estimated Fair Value	246
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents	0
Marketable securities	$ 246

Fair Value Measurements - Sche

Fair Value Measurements - Schedule of Available for Sale Securities Maturities (Details) $ in Millions	Apr. 02, 2017USD ($)
Cost Basis
Due within one year	$ 16,571
Due after one year through five years	10,280
Due after five years through ten years	0
Total debt securities	26,851
Fair Value
Due within one year	16,568
Due after one year through five years	10,240
Due after five years through ten years	0
Total debt securities	$ 26,808

Fair Value Measurements - Fin38

Fair Value Measurements - Financial Liabilities not Measured at Fair Value (Details) - USD ($) $ in Millions	Apr. 02, 2017	Jan. 01, 2017
Financial Liabilities
Current Debt	$ 5,355	$ 4,684
Non-Current Debt
Non-Current Debt	27,015	$ 22,442
Carrying Amount
Financial Liabilities
Current Debt	5,355
Non-Current Debt
Non-Current Debt	27,015
Estimated Fair Value
Financial Liabilities
Current Debt	5,355
Non-Current Debt
Non-Current Debt	$ 28,475
5.15% Debentures due 2018
Non-Current Debt
Debt Instrument, Interest Rate, Stated Percentage	5.15%
5.15% Debentures due 2018 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 899
5.15% Debentures due 2018 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 942
1.65% Notes due 2018
Non-Current Debt
Debt Instrument, Interest Rate, Stated Percentage	1.65%
1.65% Notes due 2018 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 601
1.65% Notes due 2018 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 605
4.75% Notes due 2019 (1B Euro 1.0725)
Non-Current Debt
Debt Instrument, Interest Rate, Stated Percentage	4.75%
4.75% Notes due 2019 (1B Euro 1.0725) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,069
4.75% Notes due 2019 (1B Euro 1.0725) | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,204
1.875% Notes due 2019
Non-Current Debt
Debt Instrument, Interest Rate, Stated Percentage	1.875%
1.875% Notes due 2019 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 501
1.875% Notes due 2019 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 505
0.89% Notes due 2019
Non-Current Debt
Debt Instrument, Interest Rate, Stated Percentage	0.89%
0.89% Notes due 2019 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 300
0.89% Notes due 2019 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 301
1.125% Notes due 2019
Non-Current Debt
Debt Instrument, Interest Rate, Stated Percentage	1.125%
1.125% Notes due 2019 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 699
1.125% Notes due 2019 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 696
3% Zero Coupon Convertible Subordinated Debentures due in 2020
Non-Current Debt
Debt Instrument, Interest Rate, Stated Percentage	3.00%
3% Zero Coupon Convertible Subordinated Debentures due in 2020 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 83
3% Zero Coupon Convertible Subordinated Debentures due in 2020 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 142
2.95% Debentures due 2020
Non-Current Debt
Debt Instrument, Interest Rate, Stated Percentage	2.95%
2.95% Debentures due 2020 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 546
2.95% Debentures due 2020 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 566
3.55% Notes due 2021
Non-Current Debt
Debt Instrument, Interest Rate, Stated Percentage	3.55%
3.55% Notes due 2021 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 447
3.55% Notes due 2021 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 473
2.45% Notes due 2021
Non-Current Debt
Debt Instrument, Interest Rate, Stated Percentage	2.45%
2.45% Notes due 2021 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 349
2.45% Notes due 2021 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 355
1.65% Notes due 2021
Non-Current Debt
Debt Instrument, Interest Rate, Stated Percentage	1.65%
1.65% Notes due 2021 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 997
1.65% Notes due 2021 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 986
0.250% Notes due 2022 (1B Euro 1.0725)
Non-Current Debt
Debt Instrument, Interest Rate, Stated Percentage	0.25%
0.250% Notes due 2022 (1B Euro 1.0725) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,069
0.250% Notes due 2022 (1B Euro 1.0725) | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,072
2.25% Notes due 2022
Non-Current Debt
Debt Instrument, Interest Rate, Stated Percentage	2.25%
2.25% Notes due 2022 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 994
2.25% Notes due 2022 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 995
6.73% Debentures due 2023
Non-Current Debt
Debt Instrument, Interest Rate, Stated Percentage	6.73%
6.73% Debentures due 2023 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 249
6.73% Debentures due 2023 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 310
3.375% Notes due 2023
Non-Current Debt
Debt Instrument, Interest Rate, Stated Percentage	3.375%
3.375% Notes due 2023 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 807
3.375% Notes due 2023 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 851
2.05% Notes due 2023
Non-Current Debt
Debt Instrument, Interest Rate, Stated Percentage	2.05%
2.05% Notes due 2023 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 497
2.05% Notes due 2023 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 486
0.650% Notes due 2024 (750MM Euro 1.0725)
Non-Current Debt
Debt Instrument, Interest Rate, Stated Percentage	0.65%
0.650% Notes due 2024 (750MM Euro 1.0725) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 799
0.650% Notes due 2024 (750MM Euro 1.0725) | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 805
5.50% Notes due 2024 (500 MM GBP 1.2474)
Non-Current Debt
Debt Instrument, Interest Rate, Stated Percentage	5.50%
5.50% Notes due 2024 (500 MM GBP 1.2474) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 617
5.50% Notes due 2024 (500 MM GBP 1.2474) | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 804
2.45% Notes due 2026
Non-Current Debt
Debt Instrument, Interest Rate, Stated Percentage	2.45%
2.45% Notes due 2026 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,989
2.45% Notes due 2026 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,915
2.95% Notes due 2027
Non-Current Debt
Debt Instrument, Interest Rate, Stated Percentage	2.95%
2.95% Notes due 2027 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 995
2.95% Notes due 2027 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 996
1.150% Notes due 2028 (750MM Euro 1.0725)
Non-Current Debt
Debt Instrument, Interest Rate, Stated Percentage	1.15%
1.150% Notes due 2028 (750MM Euro 1.0725) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 796
1.150% Notes due 2028 (750MM Euro 1.0725) | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 805
6.95% Notes due 2029
Non-Current Debt
Debt Instrument, Interest Rate, Stated Percentage	6.95%
6.95% Notes due 2029 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 296
6.95% Notes due 2029 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 401
4.95% Debentures due 2033
Non-Current Debt
Debt Instrument, Interest Rate, Stated Percentage	4.95%
4.95% Debentures due 2033 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 498
4.95% Debentures due 2033 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 589
4.375% Notes due 2033
Non-Current Debt
Debt Instrument, Interest Rate, Stated Percentage	4.375%
4.375% Notes due 2033 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 857
4.375% Notes due 2033 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 951
1.650% Notes due 2035 (1.5B Euro 1.0725)
Non-Current Debt
Debt Instrument, Interest Rate, Stated Percentage	1.65%
1.650% Notes due 2035 (1.5B Euro 1.0725) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,590
1.650% Notes due 2035 (1.5B Euro 1.0725) | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,646
3.55% Notes due 2036
Non-Current Debt
Debt Instrument, Interest Rate, Stated Percentage	3.55%
3.55% Notes due 2036 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 987
3.55% Notes due 2036 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 981
5.95% Notes due 2037
Non-Current Debt
Debt Instrument, Interest Rate, Stated Percentage	5.95%
5.95% Notes due 2037 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 990
5.95% Notes due 2037 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,290
3.625% Notes due 2037
Non-Current Debt
Debt Instrument, Interest Rate, Stated Percentage	3.625%
3.625% Notes due 2037 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,485
3.625% Notes due 2037 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,473
5.85% Debentures due 2038
Non-Current Debt
Debt Instrument, Interest Rate, Stated Percentage	5.85%
5.85% Debentures due 2038 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 695
5.85% Debentures due 2038 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 908
4.50% Debentures due 2040
Non-Current Debt
Debt Instrument, Interest Rate, Stated Percentage	4.50%
4.50% Debentures due 2040 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 537
4.50% Debentures due 2040 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 592
4.85% Notes due 2041
Non-Current Debt
Debt Instrument, Interest Rate, Stated Percentage	4.85%
4.85% Notes due 2041 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 296
4.85% Notes due 2041 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 345
4.50% Notes due 2043
Non-Current Debt
Debt Instrument, Interest Rate, Stated Percentage	4.50%
4.50% Notes due 2043 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 495
4.50% Notes due 2043 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 548
3.70% Notes due 2046
Non-Current Debt
Debt Instrument, Interest Rate, Stated Percentage	3.70%
3.70% Notes due 2046 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,970
3.70% Notes due 2046 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,929
3.75% Notes due 2047
Non-Current Debt
Debt Instrument, Interest Rate, Stated Percentage	3.75%
3.75% Notes due 2047 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 990
3.75% Notes due 2047 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	982
Other | Carrying Amount
Non-Current Debt
Non-Current Debt	26
Other | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 26

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Billions	3 Months Ended
	Apr. 02, 2017	Apr. 03, 2016
Income Tax (Textuals)
Effective Income Tax Rate, Continuing Operations	20.70%	15.80%
Effective Income Tax Rate Reconciliation, Business Combination, Percent	3.80%
Excess tax benefit from share based compensation	3.60%	3.10%
Unrecognized tax benefits	$ 3.1

Pensions and Other Postretire40

Pensions and Other Postretirement Benefits - Components of Net Periodic Benefit Cost (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 02, 2017	Apr. 03, 2016
Retirement Plans
Components of net periodic benefit cost
Service cost	$ 251	$ 226
Interest cost	230	233
Expected return on plan assets	(505)	(492)
Amortization of prior service cost/(credit)	0	1
Recognized actuarial losses	152	124
Curtailments and settlements	0	1
Net periodic benefit cost	128	93
Other Benefit Plans
Components of net periodic benefit cost
Service cost	61	55
Interest cost	39	40
Expected return on plan assets	(2)	(2)
Amortization of prior service cost/(credit)	(7)	(8)
Recognized actuarial losses	34	34
Curtailments and settlements	0	0
Net periodic benefit cost	$ 125	$ 119

Pensions and Other Postretire41

Pensions and Other Postretirement Benefit (Details) $ in Millions	3 Months Ended
	Apr. 02, 2017USD ($)
U.S. retirement plans
Defined Benefit Plan Disclosure [Line Items]
Contribution to pension plans	$ 17
International retirement plans
Defined Benefit Plan Disclosure [Line Items]
Contribution to pension plans	$ 10

Accumulated Other Comprehensi42

Accumulated Other Comprehensive Income (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 02, 2017	Apr. 03, 2016	Apr. 02, 2017
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	$ 70,418
Net change	379	$ 774
Ending balance	70,418		$ 70,341
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	(9,047)
Net change	395
Ending balance	(9,047)		(8,652)
Accumulated Net Investment Gain (Loss) Attributable to Parent [Member]
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	411
Net change	(90)
Ending balance	411		321
Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	(5,980)
Net change	119
Ending balance	(5,980)		(5,861)
Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member]
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	(285)
Net change	(45)
Ending balance	(285)		(330)
AOCI Attributable to Parent [Member]
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	(14,901)
Net change	379
Ending balance	$ (14,901)		$ (14,522)

Earnings Per Share (Details)

Earnings Per Share (Details) - $ / shares	3 Months Ended
	Apr. 02, 2017	Apr. 03, 2016
Reconciliation of basic net earnings per share to diluted net earnings per share
Basic net earnings per share	$ 1.63	$ 1.62
Average shares outstanding — basic	2,706,600,000	2,757,200,000
Potential shares exercisable under stock option plans	141,200,000	145,700,000
Less: shares which could be repurchased under treasury stock method	(94,600,000)	(101,100,000)
Convertible debt shares	1,300,000	2,000,000
Average shares outstanding — diluted	2,754,500,000	2,803,800,000
Diluted net earnings per share	$ 1.61	$ 1.59
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	0

Segments of Business and Geog44

Segments of Business and Geographic Areas - Sales By Segment Of Business (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 02, 2017	Apr. 03, 2016
Sales by segment of business
Sales	$ 17,766	$ 17,482
Percentage Change In Sales By Segment Of Business	1.60%
United States
Sales by segment of business
Sales	$ 9,378	9,321
Percentage Change In Sales By Segment Of Business	0.60%
International
Sales by segment of business
Sales	$ 8,388	8,161
Percentage Change In Sales By Segment Of Business	2.80%
Consumer
Segment Reporting Information [Line Items]
Gain (Loss) on Sale of Assets and Asset Impairment Charges		229
Sales by segment of business
Sales	$ 3,228	3,195
Percentage Change In Sales By Segment Of Business	1.00%
Consumer | United States
Sales by segment of business
Sales	$ 1,414	1,358
Percentage Change In Sales By Segment Of Business	4.10%
Consumer | International
Sales by segment of business
Sales	$ 1,814	1,837
Percentage Change In Sales By Segment Of Business	(1.30%)
Pharmaceutical
Sales by segment of business
Sales	$ 8,245	8,178
Percentage Change In Sales By Segment Of Business	0.80%
Pharmaceutical | United States
Sales by segment of business
Sales	$ 4,872	4,937
Percentage Change In Sales By Segment Of Business	(1.30%)
Pharmaceutical | International
Sales by segment of business
Sales	$ 3,373	3,241
Percentage Change In Sales By Segment Of Business	4.10%
Medical Devices
Sales by segment of business
Sales	$ 6,293	6,109
Percentage Change In Sales By Segment Of Business	3.00%
Medical Devices | United States
Sales by segment of business
Sales	$ 3,092	3,026
Percentage Change In Sales By Segment Of Business	2.20%
Medical Devices | International
Sales by segment of business
Sales	$ 3,201	$ 3,083
Percentage Change In Sales By Segment Of Business	3.80%

Segments of Business and Geog45

Segments of Business and Geographic Areas - Operating Profit by Segment of Business (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 02, 2017	Apr. 03, 2016
Segment Reporting Information [Line Items]
Percentage Change in Operating Income Loss	5.30%
Earnings before provision for taxes on income	$ 5,575	$ 5,294
Asset write-downs	37	82
Restructuring charges	85	120
Consumer
Segment Reporting Information [Line Items]
Gain (Loss) on Sale of Assets and Asset Impairment Charges		229
Pharmaceutical
Segment Reporting Information [Line Items]
Gain on sale of equity investments	200	100
Valuation Allowances and Reserves, Adjustments	200
Litigation Expense		136
Medical Devices
Segment Reporting Information [Line Items]
Litigation Expense		106
Asset write-downs		346
Restructuring charges	161	137
Litigation Settlement, Amount		106
Product Liability Accrual, Period Expense		148
Operating Segments [Member]
Segment Reporting Information [Line Items]
Total Segment Operating Income	$ 5,822	5,486
Percentage Change in Operating Income Loss	6.10%
Operating Segments [Member] | Consumer
Segment Reporting Information [Line Items]
Total Segment Operating Income	$ 596	566
Percentage Change in Operating Income Loss	5.30%
Operating Segments [Member] | Pharmaceutical
Segment Reporting Information [Line Items]
Total Segment Operating Income	$ 3,663	3,344
Percentage Change in Operating Income Loss	9.50%
Operating Segments [Member] | Medical Devices
Segment Reporting Information [Line Items]
Total Segment Operating Income	$ 1,563	1,576
Percentage Change in Operating Income Loss	(0.80%)
Corporate, Non-Segment [Member]
Segment Reporting Information [Line Items]
Total Segment Operating Income	$ 247	$ 192

Segments of Business and Geog46

Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 02, 2017	Apr. 03, 2016
Sales by geographic area
Sales	$ 17,766	$ 17,482
Percentage Change In Sales By Geographic Area	1.60%
UNITED STATES
Sales by geographic area
Sales	$ 9,378	9,321
Percentage Change In Sales By Geographic Area	0.60%
Europe
Sales by geographic area
Sales	$ 3,858	3,847
Percentage Change In Sales By Geographic Area	0.30%
Western Hemisphere, excluding U.S.
Sales by geographic area
Sales	$ 1,454	1,331
Percentage Change In Sales By Geographic Area	9.20%
Asia-Pacific, Africa
Sales by geographic area
Sales	$ 3,076	2,983
Percentage Change In Sales By Geographic Area	3.10%
Medical Devices [Member]
Sales by geographic area
Sales	$ 6,293	6,109
Medical Devices [Member] | UNITED STATES
Sales by geographic area
Sales	$ 3,092	$ 3,026

Business Combinations and Div47

Business Combinations and Divestitures (Details) - USD ($) $ / shares in Units, $ in Millions	Jan. 26, 2017	Apr. 02, 2017	Apr. 03, 2016	Jan. 01, 2017
Business Acquisition [Line Items]
Payments to acquire businesses		$ 4,852	$ 5
Goodwill		24,844		$ 22,805
Codman Neurosurgery [Member]
Business Acquisition [Line Items]
Proceeds from Divestiture of Businesses		1,000
Medical Devices [Member]
Business Acquisition [Line Items]
Goodwill		$ 13,646		$ 11,702
AMO [Member]
Business Acquisition [Line Items]
Weighted average useful life		14 years 6 months
AMO [Member] | Medical Devices [Member]
Business Acquisition [Line Items]
Payments to acquire businesses		$ 4,400
Finite-lived Intangible Assets Acquired		2,300
Goodwill		1,900
Actelion [Member]
Business Acquisition [Line Items]
Payments to acquire businesses	$ 30,000
Business Acquisition, Share Price	$ 280
Idorsia [Member]
Business Acquisition [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired	16.00%
Convertible Note, Equity Interest, Percentage	16.00%
Inventories [Member] | Codman Neurosurgery [Member]
Business Acquisition [Line Items]
Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent		65
Property, Plant and Equipment [Member] | Codman Neurosurgery [Member]
Business Acquisition [Line Items]
Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent		19
Goodwill [Member] | Codman Neurosurgery [Member]
Business Acquisition [Line Items]
Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent		$ 106

Legal Proceedings (Details)

Legal Proceedings (Details) $ in Millions	3 Months Ended
	Apr. 02, 2017USD ($)patentsclaimpatientclaimant	Apr. 03, 2016USD ($)
ASR
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants	2,000
Pinnacle Acetabular Cup System
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants	9,600
Pelvic Meshes
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants	55,800
Risperdal
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants	16,900
Xarelto [Member]
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants	18,400
Baby Powder [Member]
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants	3,900
Pending Litigation | Baby Powder [Member]
Legal Proceeding (Textuals)
Loss Contingency, New Claims Filed, Number | claim	2
Investigative Demands [Member]
Legal Proceeding (Textuals)
Litigation Settlement, Expense | $	$ 4
DePuy ASR U.S. | settled litigation
Legal Proceeding (Textuals)
Number of patients in settlement | patient	9,500
Medinol Ltd. [Member]
Legal Proceeding (Textuals)
Loss Contingency, Patents Allegedly Infringed, Number | patents	4
Medical Devices [Member]
Legal Proceeding (Textuals)
Litigation Settlement, Expense | $		$ 106

Restructuring (Details)

Restructuring (Details) $ in Millions	3 Months Ended
	Apr. 02, 2017USD ($)Employee	Apr. 03, 2016USD ($)
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 85	$ 120
Medical Devices [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	161
Restructuring charges recorded to date	$ 1,400
Period of workforce reduction	18 months
Number of positions eliminated | Employee	1,600
Medical Devices [Member] | Cost of Sales [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 4
Medical Devices [Member] | Other Income Expense Net [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	72
Medical Devices [Member] | Asset Write-off [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	37
Medical Devices [Member] | Other Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	124
Medical Devices [Member] | Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring estimated cost	500
Restructuring charges	0
Medical Devices [Member] | Minimum [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring estimated cost	$ 2,000
Positions eliminated (as a percent)	4.00%
Medical Devices [Member] | Maximum [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring estimated cost	$ 2,400
Positions eliminated (as a percent)	6.00%

Restructuring - Schedule of Res

Restructuring - Schedule of Restructuring Reserve (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 02, 2017	Apr. 03, 2016
Restructuring Reserve [Roll Forward]
Restructuring charges	$ 85	$ 120
Medical Devices [Member]
Restructuring Reserve [Roll Forward]
Reserve balance beginning	381
Restructuring charges	161
Payments for Restructuring	(143)
Restructuring Reserve, Settled without Cash	(37)
Reserve balance ending	362
Medical Devices [Member] | Employee Severance [Member]
Restructuring Reserve [Roll Forward]
Reserve balance beginning	380
Restructuring charges	0
Payments for Restructuring	(25)
Restructuring Reserve, Settled without Cash	0
Reserve balance ending	355
Medical Devices [Member] | Asset Write-off [Member]
Restructuring Reserve [Roll Forward]
Reserve balance beginning	0
Restructuring charges	37
Payments for Restructuring	0
Restructuring Reserve, Settled without Cash	(37)
Reserve balance ending	0
Medical Devices [Member] | Other Restructuring [Member]
Restructuring Reserve [Roll Forward]
Reserve balance beginning	1
Restructuring charges	124
Payments for Restructuring	(118)
Restructuring Reserve, Settled without Cash	0
Reserve balance ending	$ 7